

Smartphone and wearable detected atrial arrhythmias in Older Adults: Results of a fully digital European Case finding study

L Fabritz (b) ^{1,2,3,4,5,*}, DL Connolly (b) ^{4,6}, E Czarnecki⁵, D Dudek^{7,8}, E Guasch (b) ^{9,10,11}, D Haase⁵, T Huebner¹², A Zlahoda-Huzior¹³, K Jolly (b) ¹⁴, P Kirchhof (b) ^{2,3,4,5}, J Obergassel (b) ^{1,2,3}, U Schotten (b) ^{5,15}, E Vettorazzi (b) ¹⁶, SJ Winkelmann (b) ^{1,2}, A Zapf (b) ¹⁶, and RB Schnabel (b) ^{2,3,5}, and for the Smart in OAC—AFNET 9 investigators

¹University Center of Cardiovascular Science, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20251 Hamburg, Germany; ²Department of Cardiology, University Heart and Vascular Center Hamburg, Martinistr. 52, 20251 Hamburg, Germany; ³DZHK German Center for Cardiovascular Research, partner site Hamburg/Luebeck/Kiel, Germany; ⁴Institute of Cardiovascular Sciences, University of Birmingham, Edgbaston Wolfson Drive, B15 2TT Birmingham, UK; ⁵Atrial Fibrillation NETwork (AFNET), Mendelstr 11, 48149 Münster, Germany; ⁶Department of Cardiology and R&D, Birmingham City Hospital, Sandwell and West Birmingham Trust, Dudley Road, B18 7QH Birmingham, UK; ⁷Jagiellonian University Medical College, Center for Digital Medicine and Robotics, UI. Kopernika 7E, 33-332 Kraków, Poland; ⁸Maria Cecilia Hospital, Via Corriera, 1, 48033 Cotignola RA, Italy; ⁹Institut Clínic Cardio-Vascular, Hospital Clinic, University of Barcelona, Carrer de Villaroel, 170, 08036 Barcelona, CA, Spain; ¹⁰IDIBAPS, Rosselló 149-153, 08036 Barcelona, CA, Spain; ¹¹CIBERCV, Monforte de Lemos 3-5, Pabellon 11, Planta 0, 28029 Madrid, Spain; ¹²Preventicus GmbH, Ernst-Abbe-Straße 15, 07743 Jena, Germany; ¹³Department of Measurement and Electronics, AGH University of Science and Technology, Al. Mickiewicza 30, 30-059 Kraków, Poland; ¹⁴Institute of Applied Health Research, University of Birmingham, Edgbaston, B15 2TT Birmingham, UK; ¹⁵Department of Physiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center + Debyelaan 25, 6229 HX, Maastricht, The Netherlands; and ¹⁶Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Christoph-Probst-Weg 1, 20246 Hamburg, Germany

Received 22 June 2022; revised 24 October 2022; online publish-ahead-of-print 1 November 2022


Aims	Simplified detection of atrial arrhythmias via consumer-electronics would enable earlier therapy in at-risk populations. Whether this is feasible and effective in older populations is not known.
Methods and results	The fully remote, investigator-initiated Smart phone and wearable detected atrial arrhythmia in O lder A dults C ase finding study (Smart in OAC—AFNET 9) digitally enrolled participants \geq 65 years without known atrial fibrillation, not receiving oral anticoagulation in Germany, Poland, and Spain for 8 weeks. Participants were invited by media communications and direct contacts. Study procedures adhered to European data protection. Consenting participants received a wristband with a photoplethysmography sensor to be coupled to their smartphone. The primary outcome was the detection of atrial arrhythmias lasting 6 min or longer in the first 4 weeks of monitoring. Eight hundred and eighty-two older persons (age 71 ± 5 years, range 65–90, 500 (57%) women, 414 (47%) hypertension, and 97 (11%) diabetes) recorded signals. Most participants (72%) responded to adverts or word of mouth, leaflets (11%) or general practitioners (9%). Participation was completely remote in 469/882 persons (53%). During the first 4 weeks, participants transmitted PPG signals for 533/696 h (77% of the maximum possible time). Atrial arrhythmias were detected in 44 participants (5%) within 28 days, and in 53 (6%) within 8 weeks. Detection was highest in the first monitoring week [incidence rates: 1st week: 3.4% (95% confidence interval 2.4–4.9); 2nd–4th week: 0.55% (0.33–0.93)].
Conclusion	Remote, digitally supported consumer-electronics-based screening is feasible in older European adults and identifies at- rial arrhythmias in 5% of participants within 4 weeks of monitoring (NCT04579159).

^{*} Corresponding author. Tel. +4940741057980, Email: L.Fabritz@uke.de

[©] The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Graphical Abstract



Introduction

Earlier initiation of anticoagulation could prevent strokes and cardiovascular deaths in patients with atrial fibrillation (AF).^{1–4} Recently controlled clinical trials demonstrate that population-based screening for AF and subsequent initiation of oral anticoagulation can prevent some strokes.^{5,6} These trials led to recent recommendations in a practical guide of the European Heart Rhythm Association (EHRA) to intermittently screen individuals aged \geq 75 years and consider systematic screening in individuals aged \geq 65 years with additional comorbidities contributing to stroke risk.⁷ However, these studies also illustrate relatively high numbers needed to screen. Recent trials have shown that patient-operated ECG monitors can be rolled out to preselected screening populations.⁵ Implanted cardiac monitors are associated with a high analysable monitoring time,⁶ but involve invasive procedures. Simple, scalable methods to identify atrial arrhythmias in at-risk populations are needed to enable the timely detection of AF and initiation of therapy.

Continuous rhythm screening using implanted pacemakers or ECG monitors detects short atrial arrhythmias in up to 30% of elderly participants,^{6,8} but is limited by its invasive nature. Atrial arrhythmias that are only detected during many months of monitoring must statistically occur less often or be of shorter durations than arrhythmias that occur more often and are longer and therefore are more likely to be detected in shorter monitoring periods.^{6,9,10} Indeed, subclinical AF detected in implantable cardiac devices is associated with a lower stroke risk than clinical AF,^{9–11} although a cut-off point for increased stroke risk remains to be found and validated.^{12–14} Modern consumer electronics, including smartphones and smartwatches or wearablebased devices,^{15–17} enable recording of pulse plethysmography (PPG). Combined with validated analysis algorithms,^{18,19} this can be applied to monitor for arrhythmias.¹⁹ Wearable-based screening for atrial arrhythmias is feasible when company-owned data are analysed in relatively young, early adopters.^{15–17,19,20} An analysis of previously reported atrial arrhythmia detection rates with wearables is summarized in Table 2 and Supplementary material online, Figure S1. The US Screening Task Force and an EHRA practical guide recognized the potential of PPG-based arrhythmia screening,⁷ but noted that more evidence was needed before it could be recommended,¹ especially regarding arrhythmia screening in older populations.^{1,5,6} Inclusive methods offering PPG-based arrhythmia screening to older participants are therefore required.

To address this societal need, the **Smart**phone and wearable detected atrial arrhythmia **in O**lder **A**dults **C**ase finding study (Smart in OAC—AFNET 9) evaluated the usability of a fully digital, PPG-based detection system for atrial arrhythmias in older European adults.²¹

Methods

Study design

Smart in OAC—AFNET 9 is an investigator-initiated, single-arm, international, multicentre case-finding study in an at-risk population without

previously known AF using a low-threshold, digitally enhanced screening platform (https://clinicaltrials.gov/ct2/show/NCT04579159). Details of the study design have been published.²¹ The study has been approved by the local Ethics Committees in all participating sites [Hamburg 2020-10260-BO-ff, Dresden (Markkleeberg) EK-BR-95/21-1, Barcelona HCB/2021/0255, Krakow/Nowy Sasz 298/KBL/OIL/2020, Birmingham, UK IRAS 292218]. To capture societal and health care realities in different parts of Europe, the study was planned in Germany (Central Europe), Poland (Eastern Europe), Spain (Western Europe), and the UK (central NHS system). In the UK, administrative delays due to COVID-19 prevented the study from commencement in time. Sponsor of the trial is AFNET (https://www.kompetenznetzvorhofflimmern.de). Financial support came from Daiichi-Sankyo Europe in the form of an unrestricted grant and by Preventicus, lena, Germany, as an in-kind contribution.

Participants

Potential participants aged 65 years or older without known AF and not on oral anticoagulation were made aware of the study using newspaper and television advertisements targeting audiences of older adults, senior citizen interest groups, personal contacts in the sites, general physicians in the community, leaflets, and a website.

Study intervention. Within the limitations of a case finding study requiring consent, the system was designed for simplicity. After expressing interest and agreeing to be contacted using digital, oral, or written communication, potential participants were offered participation. Informed consent was obtained digitally. Paper versions were available on demand and were required in Spain. A wristband with a PPG sensor (Corsano 287, MMT SA, Switzerland) was shipped to consenting participants or collected at the site. Participants installed the Corsano Preventicus Smart app onto their smartphone (operating system requirements Apple iOS version 12.2 or higher or Android 8.0 or higher) and coupled the wristband via Bluetooth for app-transferal of PPG data. The wearable technology records and transfers passively around the clock, operating for up to 5 days between recharging. Participants were asked to wear the wristband and use the system for 4 weeks with the possibility to extend monitoring for up to 8 weeks if atrial arrhythmias had not been found. Analysis of the pulse waves for atrial arrhythmias used a validated algorithm (Class IIa CE certified medical product, Preventicus Heartbeats®, Jena, Germany, www.preventicus.com,^{18,19}). All signals were centrally analysed by a cloud-based and device-agnostic analytic service (Preventicus Heartbeats, CE marked certified medical device.²¹) Although the Corsano wristband was used and the app was adapted to Corsano technology, any other high-quality PPG wristband could be used in the future.

The PPG was continuously recorded with the wristband and split in 1 min-long segments, each of them analysed via the atrial arrhythmia detection algorithm. One-minute recordings were excluded automatically if more than 10% of the signal had poor quality, e.g. from movement artefacts. Length of atrial arrhythmia episodes was estimated via consecutive positive one-minute segments and atrial arrhythmias in this study were defined as periods of an irregular PPG signal lasting six minutes or longer or a burden of 1.5% per 24 h or more.²¹ Atrial arrhythmias of this duration detected by implanted devices are associated with an increased risk of stroke.^{10,22} PPG analysis was stopped after the detection of atrial arrhythmias.

To ensure that participants would be reassured or receive a diagnosis of AF and subsequent treatment as required despite restrictions of health services during the pandemic, all participants with positive PPG atrial arrhythmia screening were offered a 14-day external loop recorder Holter ECG (CardioMem® CM 100 XT), delivered by post or handed out on site. The same loop recorder was also planned to be offered to a random sample of participants without PPG detection of atrial arrhythmias, while the delivery of Holter ECG recorders to positively PPG screened participants was prioritized.

Data collection

Information on name, mobile number, date of birth, known AF, and current oral anticoagulation was entered by the participants via their smartphone at enrolment and during the screening process (*Table 1*). The results of the PPG analyses and the Holter ECG were captured on the systems described above and integrated into the final data set for analysis. The results of this investigation were made available to the site teams for medical action.




Figure 1 STROBE flow chart of the study. FAS, full analysis sample.

	Total (n = 882)	without atrial arrhythmias (n = 838)		P-value
Age				0.008 ¹
Mean \pm SD,	70.9 ± 4.9	70.8 ± 4.8	72.8 ± 5.7	
Median (Q1, Q3)	70.0 (67.0, 74.0)	69.0 (67.0, 74.0)	71.5 (68.8, 75.2)	
Range	65.0–90.0	65.0–90.0	65.0-86.0	
Sex				0.797 ²
female	500 (56.7%)	473 (56.4%)	27 (61.4%)	
male	381 (43.2%)	364 (43.4%)	17 (38.6%)	
other	1 (0.1%)	1 (0.1%)	0 (0.0%)	
Country	(((((((((((((((((((((((((((((((((((((((. (0.1.70)		0.914 ²
Germany	575 (65.2%)	546 (65.2%)	29 (65.9%)	0.711
Poland	277 (31.4%)	263 (31.4%)	14 (31.8%)	
Spain	30 (3.4%)	29 (3.5%)	1 (2.3%)	
data source	50 (5.7%)	27 (3.5%)	1 (2.5%)	0.963 ²
GP	Q0 (0 10/)	76 (0 19/)	1 /0 10/1	0.703
	80 (9.1%)	76 (9.1%) 19 (2.2%)	4 (9.1%)	
Hospital	20 (2.3%)	19 (2.3%)	1 (2.3%)	
Leaflet	96 (10.9%)	92 (11.0%)	4 (9.1%)	
Other	633 (71.8%)	600 (71.6%)	33 (75.0%)	
Pharmacy	15 (1.7%)	15 (1.8%)	0 (0.0%)	
Website	38 (4.3%)	36 (4.3%)	2 (4.5%)	2
Measurement bracelet received				0.619 ²
Post	469 (53.2%)	444 (53.0%)	25 (56.8%)	
Site	413 (46.8%)	394 (47.0%)	19 (43.2%)	
Ethnic origin				0.965 ²
Arab	2/851 (0.2%)	2/808 (0.2%)	0/43 (0.0%)	
Asian	2/851 (0.2%)	2/808 (0.2%)	0/43 (0.0%)	
Mixed	2/851 (0.2%)	2/808 (0.2%)	0/43 (0.0%)	
Other	62/851 (7.3%)	58/808 (7.2%)	4/43 (9.3%)	
White	783/851 (92.0%)	744/808 (92.1%)	39/43 (90.7%)	
Hypertension				0.543 ²
No	439/853 (51.5%)	416/812 (51.2%)	23/41 (56.1%)	
Yes	414/853 (48.5%)	396/812 (48.8%)	18/41 (43.9%)	
Diabetes mellitus	. ,		· · · · ·	0.057 ²
No	762/859 (88.7%)	720/816 (88.2%)	42/43 (97.7%)	
Yes	97/859 (11.3%)	96/816 (11.8%)	1/43 (2.3%)	
EQ-5D: mobility	()		· · · · ·	0.522 ³
Nmiss	331	313	18	
l have no problems in walking about	471 (85.5%)	449 (85.5%)	22 (84.6%)	
I have slight problems in walking about	51 (9.3%)	50 (9.5%)	1 (3.8%)	
I have moderate problems in walking about	26 (4.7%)	23 (4.4%)	3 (11.5%)	
I have severe problems in walking about	3 (0.5%)	3 (0.6%)	0 (0.0%)	
l am unable to walk about	0 (0.0%)	0 (0.0%)	0 (0.0%)	
EQ-5D: self-care	0 (0.0%)	0 (0.0%)	0 (0.0%)	0.158 ³
•	221	212	10	0.158
Nmiss	331	313	18	
I have no problems washing or dressing myself	538 (97.6%)	513 (97.7%)	25 (96.2%)	
I have slight problems washing or dressing myself	11 (2.0%)	11 (2.1%)	0 (0.0%)	
I have moderate problems washing or dressing myself	2 (0.4%)	1 (0.2%)	1 (3.8%)	
I have severe problems washing or dressing myself	0 (0.0%)	0 (0.0%)	0 (0.0%)	
l am unable to wash or dress myself	0 (0.0%)	0 (0.0%)	0 (0.0%)	-
EQ-5D: usual activities				0.666 ³
Nmiss	330	312	18	

Table 1 Continued

	Total (n = 882)	without atrial arrhythmias (n = 838)	with atrial arrhythmias (<i>n</i> = 44)	P-value
I have no problems doing my usual activities	498 (90.2%)	475 (90.3%)	23 (88.5%)	
l have slight problems doing my usual activities	41 (7.4%)	39 (7.4%)	2 (7.7%)	
I have moderate problems doing my usual activities	13 (2.4%)	12 (2.3%)	1 (3.8%)	
I have severe problems doing my usual activities	0 (0.0%)	0 (0.0%)	0 (0.0%)	
I am unable to do my usual activities	0 (0.0%)	0 (0.0%)	0 (0.0%)	
EQ-5D: Pain and discomfort				0.509 ³
Nmiss	334	316	18	
l have no pain or discomfort	316 (57.7%)	300 (57.5%)	16 (61.5%)	
l have slight pain or discomfort	172 (31.4%)	164 (31.4%)	8 (30.8%)	
l have moderate pain or discomfort	48 (8.8%)	46 (8.8%)	2 (7.7%)	
l have severe pain or discomfort	11 (2.0%)	11 (2.1%)	0 (0.0%)	
l have extreme pain or discomfort	1 (0.2%)	1 (0.2%)	0 (0.0%)	
EQ-5D: anxiety and depression				0.232 ³
Nmiss	329	311	18	
l am not anxious or depressed	447 (80.8%)	423 (80.3%)	24 (92.3%)	
l am slightly anxious or depressed	83 (15.0%)	82 (15.6%)	1 (3.8%)	
I am moderately anxious or depressed	21 (3.8%)	20 (3.8%)	1 (3.8%)	
l am severely anxious or depressed	1 (0.2%)	1 (0.2%)	0 (0.0%)	
l am extremely anxious or depressed	1 (0.2%)	1 (0.2%)	0 (0.0%)	
EQ-5D VAS				0.454 ¹
Nmiss	331	313	18	
Mean ± SD	82.9 ± 12.8	83.0 ± 12.6	81.1 ± 17.6	
Median (Q1, Q3)	85.0 (80.0, 91.0)	85.0 (80.0, 91.0)	86.0 (80.0, 90.0)	
Range	20.0-100.0	29.0-100.0	20.0-100.0	
EQ-5D 5L VT score				0.566 ¹
Nmiss	339	321	18	
Mean \pm SD	0.95 ± 0.08	0.95 ± 0.09	0.96 ± 0.06	
Median (Q1, Q3)	0.97 (0.92, 1.00)	0.97 (0.92, 1.00)	1.00 (0.94, 1.00)	
Range	0.28–1.00	0.28–1.00	0.80–1.00	

Baseline characteristics of the study population grouped by AA detection within the first 28 days. Categorical data are n (%) or n/valid n (%) in case of missing values. Age is presented as mean \pm SD, EQ-5D VAS, and EQ-5D 5L VT Score as median (IQR). EQ-5D VAS was missing for total n = 331, without AA n = 313, with AA n = 18, EQ-5D 5L VT Score was missing for n = 339/321/18. (1) Linear Model ANOVA, (2) Pearson's χ^2 test, (3) Trend test for ordinal variables.

(1) Student's t-test, (2) Pearson's χ^2 , (3) Armitage trend test for ordinal variables, Nmiss, number of missing values; GP, general practitioner.

Preventicus data management and data protection comply with General Data Protection Regulations. Personal data (declarations of consent, contact information, etc.) were stored exclusively in a defined cloud workspace (Preventicus Caresafe). The data in the Caresafe were end-to-end encrypted, limiting access to personal data to study site staff. Preventicus did not have any access to the personal data of participants.

Statistical considerations

Sample size

AA are detected in circa 30–40% of elderly populations when continuous monitoring is applied for 2–3 years using implantable loop recorders.^{6,8,23} Integrating the estimated effects of shorter monitoring times (1 month), considering that the wearable will not record continuously due to noise and the need for charging, and based on the known effects of intermittent and shorter ECG monitoring on detection rates of short AA,^{9,17,24} we assumed a detection rate of AA of 3–6% in the screening population.²¹ A sample size of 1000 participants would allow us to estimate a rate of detection of 5% with a precision of 2.8% (width of the two-sided

95% Clopper-Pearson confidence interval (Cl), PASS 16.0.3), a sample size of 750 gives a precision of 3.3%.

Primary outcome

The primary outcome parameter of this study is the prevalence of PPG-detected atrial arrhythmias (lasting six minutes or longer), calculated as the number of participants with AA detected by the wearable in relation to all included participants. The primary analysis assessed atrial arrhythmias detected in 4 weeks of monitoring.

Secondary outcomes

Secondary outcomes include the total number of participants with atrial arrhythmias over the entire 8-week recording; time from enrolment to AA detection with death as a competing risk; regional differences in AA detection and differences by route of invitation; quality of life estimated by EQ-5D-5L in participants with and without AA; detection of AF by ECG, compliance, and reasons for non-participation.

Grand politikou, and otor, mutual and colord, and and colord, and and and and and and and and colord, and and and and and and and and and colord, and and and and and and and colord, and and and and and and colord, and and and and and and colord, and and and colord, and and and and colord, and and and and and and and colord, and and and colord, and and and colord, and and and and and and and colord, and and and colord, and and and colord, and and and and and and and colord, and and colord, and and colord, and and colord, and and colord, a	Grunnoi interaction <	Study	Monitoring	Monitoring Technique	Author, study acronym subgroup/own analysis	Population	Design, intervention	Mean age (+/– Std.)	Female (%)	n ar	Atrial arrhythmia IR (%)
Langer et al. 2021 ³⁹ AVVARE-AF program Gladstone et al. 2021 ³⁰ SCREEN-AF SCREEN-AF Kemp Gudmundsdottir et al. 2020 ³¹ Kemp Gudmundsdottir et al. 2020 ³¹ Rooney et al. 2019 ³² ARIC Steinhubl et al. 2018 ³³ ARIC Steinhubl et al. 2019 ³³ hESA (substudy) Perez et al. 2019 ¹⁵ Apple Heart Study own analysis of participants aged 2 65 years Guo et al. 2019 ¹⁵ Pre-MAFA II (Huawei Heart Study) own analysis of participants aged 2 55 years Lubitz et al. 2021 ²⁰ FITBIT Heart Study Design paper	Lunger et al. 201 ¹¹ Community bands, recruted form outpatient carcielogy Region: Separate carcieoox, 7 days Bedata: injek 73 ² 6 ² 73 ² AVARE-4F pingtam casta Agge 2 S (Tacheor) 2 1 d posit, Ti The o 2 S S sent al exist. 201 201 201 Casta Agge 2 S (Tacheor) 2 1 d posit, Ti The o 2 S S sent al exist. Casta Agge 2 S (Tacheor) 2 1 d posit, Ti The o 2 S S sent al exist. 201 201 S Glademer et al 200 ¹¹ Canata genetant CDOs S COLO EX Canata genetant CDOs S COLO EX 201 201 201 S Glademer et al 200 ¹¹ Canata genetant CDOS S COLO EX ange bed ECC Detect Zafahan 201 201 S CREN 4F Canata genetant CDOS S COLO EX Separate S COLO Excet Zafahan 201 201 S CREN 4F Canata genetal Region US Age 2 S S sent Houlon: Separate S CO Detect Zafahan 201 201 R Monto Community based Region US Age 2 S S sent Houlon: Separate S CO Detect Zafahan 201 201 R Monto Community Based Region US A Region US	General population/ community based/at risk cohorts, remote	Continuous monitoring	single lead ECG		General population based Region: K Age: ≥ 64 Inclusion: CHA ₃ D5 ₂ -VASc ≥ 4 in woman or ≥ 3 in men Exclusion: Known AF: excluded	Sequence: continuous, 14 days Biodata: single lead ECG Device: ZioPatch		Analysis ongoin	g/unpublish	þər
ANAVACE-WE program canataa Age: 20 HF, HT, DM, CKD, OSAS, CVD, FF, 33%, significant DDys Exclusion: implanted PM/ICD Known AF: sculuded Gladstoore et al. 2021 ¹⁰ General population based, recurited from GP practices Region: SCREENAF Kemp Gudmundsdottir et al. 2020 ¹¹ General population based, recurited from GP practices Region: SCREENAF Kemp Gudmundsdottir et al. 2019 ¹² General population based Region: Scocholm Age: 75 or 76 years STROKESTOP II High-risk subgroup General population based Region: Scocholm Age: 75 or 76 years STROKESTOP II High-risk subgroup General population based Region: Scocholm Age: 75 or 76 years Stronow et al. 2019 ¹³ General population based Region: Scocholm Age: 75 or 76 years Roomey et al. 2019 ¹³ General population based Region: USA Age: 275 years Inclusion: Known AF: excluded Strohubel et al. 2019 ¹³ General population based Region: USA Age: 275 years Inclusion: Known AF: excluded Steinhubl et al. 2018 ¹³ General population based Region: USA Age: 275 years Inclusion: Exclusion: mplantable PM/ICD, on OAC, Inown AF, Roown AF. MET A Minter Known AF: excluded Met A Agustor: Timplantable PM/ICD, on OAC, Inown AF, Roown AF. MET A Stronorn AF: Orgonality Indusion: Exclusion: stronantices) Region: USA Age: 21 years Inclusion: Fordusion: Exclusion: Agustor MET A Stronard Age: 75 years Inclusion: Exclusion: Stronard Age: 71 nonordify Indusion: Exclusion and Age: 71 nonordify Indusion: Bae MET A <t< td=""><td>Annoto-opegan Calabrative et al. 2001¹ Calabrative et al. 2001¹ Set al. 2001¹</td><td></td><td></td><td></td><td></td><td>Community based, recruited from outpatient cardiology Region: 5</td><td>equence: continuous, 7 days Biodata: single</td><td>78.7±6.1</td><td>42%</td><td>942</td><td>2.7 (1.8–4.0)</td></t<>	Annoto-opegan Calabrative et al. 2001 ¹ Calabrative et al. 2001 ¹ Set al. 2001 ¹					Community based, recruited from outpatient cardiology Region: 5	equence: continuous, 7 days Biodata: single	78.7±6.1	42%	942	2.7 (1.8–4.0)
significant DDys Exclusion: implanted PMI/CD Known AF: cadatore et al. 2021 ³⁰ General population based. recruited from GF practices Region: SCREEN+F Canada, Germany Age: 275 years Inclusion: CHADDS ₂ 2 Exclusion: implantable PMI/CD/ILR, contraindication for OAC Known AF: excluded Kemp Gudmundsdottir et al. 2020 ³¹ General population based Region: Stochholm Age: 75 or 76 years STROKESTOP II High-risk subgroup ceneral population based Region: Stochholm Age: 75 or 76 years Kemp Gudmundsdottir et al. 2019 ³² Ceneral population based Region: Stochholm Age: 75 or 76 years ARIC Community based Region: USA Age: 275 years Inclusion: ARIC Community based Region: USA Age: 275 years Inclusion: Fieihubl et al. 2019 ³³ General population based Region: USA Age: 275 years Inclusion: Fieihubl et al. 2019 ⁴³ General population based Region: USA Age: 275 years recluded Steinhubl et al. 2019 ⁴⁴ General population based Region: USA Age: 275 years recluded Mitter Known AF: excluded Fieithert et al. 2019 ⁴⁴ General population based Region: USA Age: 215 years recluded Proc Act Act Act Act Act Act Act Act Act Ac	significant DDys Ecutation implanted PMICD Knoon AF: significant DDys Ecutation implanted PMICD Knoon AF: 401 374 431 Calabiton et al. 2021 ¹⁰ General population insubine PMICDUK, correardization for OAC significant ECO Envice Zehheth 80±4 376 440 331 Kenduore et al. 2021 ¹⁰ General population insubine PMICDUK, correardization for OAC single last ECC Device Zehheth 80±4 376 440 331 Kenduore et al. 2009 ¹¹ General population insubine PMICDUK, correardization for OAC single last ECC Device Zehheth 373±40 580 234 231 Kenny Gummade et al. 2008 ¹¹ General population insufficient for OAC single last ECC Device Zehheth 373±40 580 234 231					Canada Age:≥ 65 Inclusion:≥ 1 of poAF, 51/11A or≥ /5 years old+ ≥ 2 of HF, HT, DM, CKD, OSAS, CVD, EF < 35%,	lead ECG Device: Cardiostat, Canada				
accuraci accuraci Gladstone et al. 2021 ¹⁰ General population based. recruited from GP practices Region. SCREEN-AF Canada, Germany Age: 25 years inclusion: CHAD5,2 2 Fxclusion: implantable PMI/CD/ILR, contrandication for OAC Known AF: excluded Kemp Gudmundsdottir et al. 2020 ¹¹ General population based Region: Stockholm Age: 75 or 76 years STROKESTOP II High-risk subgroup Old Inclusion: NT-proBNP 2 125 ng/L Exclusion: -Known AF: excluded Rooney et al. 2019 ¹³ Community based Region: USA Age: 275 years inclusion: ARIC Ronney et al. 2018 ¹³ Community based Region: USA Age: 275 years inclusion: Exclusion: Insplantable PMI/CD/ILR, skin allergit Known AF: Excluded InSToPS General population based Region: USA Age: 275 years inclusion: Insplantable PMI/CD/ILR, skin allergit Known AF: Excluded March General population based Region: USA Age: 275 years inclusion: Insom March General population based Region: USA Age: 275 years inclusion: Insom March General population based Region: USA Age: 276 years inclusion: Insom March General population based Region: USA Age: 276 years inclusion: Insom	Cubbione et al. 2011 ¹⁰ General population bare cubord Secured Secured<					significant DDys Exclusion: implanted PM/ICD Known AF:					
Gladstone et al. 2021 ¹⁰ General population based, recruited from GP practices Region: SCREEN.AF Canada, Germany Age: 275 years Inclusion: CHADDS _{2,2} 2 Kemp Gudmundsdottir et al. 2020 ¹¹ Known AF: excluded Known AF: excluded Kemp Gudmundsdottir et al. 2020 ¹¹ General population based Region: Strockholm Age: 75 or 76 years STROKESTOP II High-risk subgroup Known AF: excluded Ronney et al. 2019 ¹² General population based Region: USA Age: 275 years Inclusion: Ronney et al. 2018 ¹³ ARIC Community based Region: USA Age: 275 years Inclusion: Exclusion: implantable PM/ICD/IIR, siun allergic Known AF: sparated Steinhubl et al. 2018 ¹³ Community based Region: USA Age: 275 years Inclusion: Exclusion: implantable PM/ICD/IIR, siun allergic Known AF: sparated Steinhubl et al. 2018 ¹³ General population based Region: USA Age: 275 years inclusion: Exclusion: implantable PM/ICD/IIR, siun allergic Known AF: scutuded MSToPS Community based Region: USA Age: 275 years inclusion: Exclusion: implantable PM/ICD/IIR, siun allergic Known AF: scutuded MSToPS General population based Region: USA Age: 275 years inclusion: Exclusion: implantable PM/ICD/III, siun allergic Known AF: scutuded MSToPS General population based Region: USA Age: 275 years inclusion: Exclusion: inplantable PM/ICD/III, siun allergic Known AF: scutuded MSToPS Matter Known AF: excluded Heckbert et al. 2018 ³ General population based Region: USA Age: 218 years inclusion: Apple Heart Study own onroyis of participants Genera	Cuestion of charany Age: 27 yean futuator: CHADS_2.2 single lad ECC Dovie: 20Petri 81,4 57% 434 531 Komp Cambonany Age: 75 yean futuator: CHADS_2.2 single lad ECC Dovie: 20Petri 81,4 57% 44 531 Komp Cambonany Age: 75 yean futuator: CHADS_2.2 single lad ECC Dovie: 20Petri 81,4 57% 44 531 Komp Cambonany Age: 75 yean futuation for CHADS_2.2 single lad ECC Dovie: 20Petri 73,4 2376 443 STROKETOP II High-risk subgroup di Inclusion: NT-proBNP 2.15 rg/L Eccision: Koown AF: and afge: 50,5% single lad ECC Dovie: 20Petri 232,4 237 ARC Educar: inplantable FPICDUR, stantaper Scionon AF: and afge: 50,5% single lad ECC Dovie: 20Petri<					excluded					
Exclusion: implantable PM/ICD/ILR, contraindication for OAC Kemp Gudmundsdottir et al. 2020 ³¹ General population based Region: Stockholim Age: 75 or 76 years STROKESTOP II High-risk subgroup old inclusion: NT-proBNP ≥ 125 ngL Exclusion: Known AF: Rooney et al. 2019 ³³ old inclusion: NT-proBNP ≥ 125 ngL Exclusion: Known AF: Rooney et al. 2019 ³³ community based Region: USA Age: 275 years Inclusion: Facinhubl et al. 2018 ³³ Community based Region: USA Age: 275 years Inclusion: Facinhubl et al. 2018 ³³ General population based (all subscribers of a certain health care mST oPS General population based (all subscribers of a certain health care MST oPS Mantter Known AF: excluded Heckbert et al. 2018 ³⁴ General population based (b communities) Region: USA Age: 275 years inclusion: Fexcluded Heckbert et al. 2018 ³⁴ MST oPS Mantter Known AF: excluded Heckbert et al. 2018 ³⁴ General population based (b communities) Region: USA Age: 275 years inclusion: Fexcluded Reform AT: known AF: excluded MESA (substudy) UB years inclusion: Exclusion: USA Age: 218 years Matter Known AF: excluded Apple Watch owner Exclusion: USA Age: 218 years Refor out al. 2019 ¹⁶ General population based Region: USA Age: 218 years	Reing Gudmundidetir et al. 2019 ¹ Contrantetaction for OAC N/A 60% 3766 410 Kemp Gudmundidetir et al. 2019 ¹¹ General population based Region: Schlom Agr: 50 75 yes site place continuous, 14 days Bodatir. N/A 60% 3766 410 Roove et al. 2019 ¹¹ General population based Region: Schlom Agr: 50 75 yes in Rejearce continuous, 14 days Bodatir. 732, 446 58% 2204 2307 Roove et al. 2019 ¹¹ Communy based Region: Schlom Agr: 50 years in Rejearce Continuous, 14 days Bodatir. 732, 446 58% 2307 Roove et al. 2019 ¹¹ Communy based Region: USA Agr: 27 years in Rejearce CO Actinuous, 14 days Bodatir. 732, 416 58% 2307 ARIC General population based (Bi subcritere of a certain health cree Continuous, 14 days Bodatir. 733, 210 410 ARIC General population based (Bi subcritere of a certain health cree Continuous, 14 days Bodatir. 733, 210 410 ARIC General population based (Bi subcritere of a certain health cree Continuous, 14 days Bodatir. 732, 416 58% 2104 ARIC General population based (Bi subcritere of a certain health cree Sequence continuous, 14 days Bodatir. 732, 416 732, 416 732, 416 </td <td></td> <td></td> <td></td> <td></td> <td>General population based, recruited from GP practices Region: Carada, Germany Age: \geq 75 years inclusion: CHADS₂ \geq 2</td> <td>Sequence: continuous, 14 days Biodata: single lead ECG Device: ZioPatch</td> <td>80±4</td> <td>57%</td> <td>434</td> <td>5.3 (3.4–8)</td>					General population based, recruited from GP practices Region: Carada, Germany Age: \geq 75 years inclusion: CHADS ₂ \geq 2	Sequence: continuous, 14 days Biodata: single lead ECG Device: ZioPatch	80±4	57%	434	5.3 (3.4–8)
Known AF: Known AF: excluded Kemp Gudmundsdottir et al. 2020 ¹¹ General population based Region: Stockholm Age: 75 or 76 years STROKESTOP II High-risk subgroup old Inclusion: NT-proBNP \geq 125 ng/L Exclusion: -Known AF: Rooney et al. 2019 ¹² Community based Region: USA Age: 275 years Inclusion: ARIC Exclusion: implantable PM/ICD/IIR, skin allergic Known AF: Rooney et al. 2018 ¹³ General population based (all subscribers of a certain health care InSTOPS Damor Miltip or a stated Steinhubl et al. 2018 ¹³ General population based (all subscribers of a certain health care InSTOPS Pan9 Regior: USA Age: 275 years or 265 years + Female + 1 Comorbidity on OAC, known AF: excluded Heckbert et al. 2018 ¹⁴ General population based (all subscribers of a certain health care Minter Known AF: excluded Preces et al. 2019 ¹⁵ General population based (communities) Region: USA Age: 218 years inclusion: Apple Heart Study own analysis of participants Apple Vatch own AF: excluded Rever Add Richt General population based Region: USA Age: 218 years inclusion: Apple Heart Study own analysis of participants Apple Vatch owner Exclusion: Hown AF: excluded Rever Add aged 265 years Apple Watch owner Exclusi	Kimp Gummabdurit et al. 200 ¹¹ Known AF, excluded Nink Kimp Biodrat Nink 60% 376 410 STROKESTOP H High-risk subgroup del neutonion NT peneNPP - Zing E clausion - Known AF: single lead ECC Device: Noucor R-teat + continuous, 14 days Biodrats 79.2 410 23(1) 23(1 23(1) 23(1 23(1) 23(1 23(1) 23(1 23(1) 23(1) 23(1) 23(1) 23(1) 23(1) 23(1) 23(1) 23(1) 23(1) 23(1)					Exclusion: implantable PM/ICD/ILR, contraindication for OAC					
Kemp Gudmundsdottir et al. 2020*1General population based Region: Stockholm Age: 75 or 76 years STROKESTOP II High-risk subgroupGeneral population: NT-proBNP \geq 125 ng/L Exclusion: -Known AF: excludedRooney et al. 2019*1Community based Region: USA Age: 275 years Inclusion: aRICCommunity based Region: USA Age: 275 years Inclusion: excludedRoiney et al. 2018*1Community based Region: USA Age: 275 years Inclusion: ansToPSCommunity based Region: USA Age: 275 years Inclusion: separatedRoiney et al. 2018*1Community based Region: USA Age: 275 years inclusion: ansToPSSteinhubl et al. 2018*1Roiney et al. 2018*1General population based (all subscribers of a certain health care pan9 Region: USA Age: 275 years or 265 years + Female + 1 comorbidity Inclusion: Exclusion: implantable PM/ICD. on OAC, known AT, known Aflutter Known AF: excluded Perez et al. 2018*1Apple Heart Study own anolysis of portropans ged 2 65 yearsGeneral population based (a communites) Region: USA Age: 218 years Inclusion: from AT, known Aflutter Known AF: excluded ged 2 65 yearsApple Heart Study own anolysis of portropans andysis of portropansApple Watch owner Exclusion: win allergy to tapefadhesives Known AF: excluded aged 2 65 yearsApple Heart Study Osegr poperApple Watch owner Exclusion: Stin allergy to tapefadhesives Known AF: excluded aged 2 65 yearsApple Heart Study Design poperApple Watch owner Exclusion: Known AF: included Counted Lutawei Heart Study Design poperFIBIT Heart Study Design poperFibit device owner Exclusion: OAC, implanted PM/ICD Known AF: excluded (AFIAFIUED)FIBIT Heart Study Design poperFibit device ownere	Kamp Guanunodotin rat al 2004 ¹ General population based Region: Stochtoin Ager 25 or 76 years Sequence continuous, 14 days Blodara. NiA 6/6 276 4410 Romov et al 2019 ¹¹ Commany based Region: Stochtoin Ager 25 syrus Inclusion: Sequence continuous, 14 days Blodara. 79.2 ± 46 56% 2244 231 ARC Exclusion: imparatale PhyliCDIIR, sun allenge Known AF: single lead ECC Device: Dovice: Alphaba 79.2 ± 46 56% 2244 231 ARC Exclusion: imparatale PhyliCDIIR, sun allenge Known AF: single lead ECC Device: ZoPatch 79.2 ± 46 56% 234 231 Stannbul et al. 2018 ¹¹ General poputation based Region: USA Age: 27 Systars vec 26 Systars + Finate + 1 single lead ECC Device: ZoPatch 79.2 ± 40 56% 241 231 ARD Ecdusion: inparatable PhyliCD: on OAC, Inown AT: Inown Angel lead ECC Device: ZoPatch 79.2 ± 40 50% 40.0 79 401 Heckbert et al. 2018 ¹¹ Barn Region: USA Age: 27 Systars vec 26 Systars + Finate + 1 single lead ECC Device: ZoPatch 79.2 ± 40 50% 241 231 24 231 24 231 24 231					Known AF: excluded					
STROKESTOP II High-risk subgroup old Inclusion: NT-proBNP \geq 15 ng/L Exclusion: excluded Rooney et al. 2019 ³³ Community based Region: USA Age: \geq 75 years Inclusion: ARC ARIC Exclusion: implantable PMI/ICD/IIR, skin allergic Known AF: separated Steinhubl et al. 2018 ³³ General population based (all subscribers of a certain health care pair MSTOPS Rooney et al. 2018 ³⁴ General population based (all subscribers of a certain health care pair MSTOPS Rooney et al. 2018 ³⁴ General population based (all subscribers of a certain health care pair MSTOPS Rooney et al. 2018 ³⁴ General population based (all subscribers of a certain health care pair MSTOPS MELLER Known AF: excluded Recore Control on OAC, known AF, known AF: excluded Prese et al. 2018 ³⁴ General population based (communities) Region: USA Age: \geq MSD Age: Arr All own AF: excluded Recore Conson: Second Age: \geq Apple Heart Study own analysis of porticipants Apple Vatch own AF: excluded Opple Heart Study own analysis of porticipants Apple Vatch owner Exclusion: -Known AF: included Apple Heart Study Design poper Apple Vatch owner Exclusion: -Known AF: included Therm Heart Study Design poper Apple Vatch owner Exclusion: -Known AF: included IFTBIT Heart Study Design poper Rhown AF: excluded (AFIAFIUED) <th< td=""><td>STROKESTOP II High-risk subgroup old Inclusion: NT-proBNP 215 sig1 Exclusion: Known AF: single lead ECG Device: Dohatch 72_±46 S8 2244 23 (1) ARC Exclusion: implantable PM/ICDIR, sina allegy Known AF: angle lead ECG Device: ZoPatch 73_±46 S8 23 (1) ARC Exclusion: implantable PM/ICDIR, sina allegy Known AF: angle lead ECG Device: ZoPatch 73_±46 S8 23 (1) Steminular tet al. 2018¹¹ General population based (all subscripes of a certim health care sommous). 2x14 days Biodita: 73_±470 41% 73 (1) 23 (1) Steminular tet al. 2018¹¹ General population based (all subscripes of a certim health care sommous). 2x14 days Biodita: 73_±470 41% 73 23 (1) Mitter Known AF: angle lead ECG Device: ZoPatch 75±8 48% 804 40.2 Mitter Known AF: angle lead ECG Device: ZoPatch 75±8 48% 804 40.2 Mitter Known AF: angle lead ECG Device: ZoPatch 75±8 48% 804 40.2 Mitter Known AF: angle lead ECG Device: ZoPatch 75±8 48% 804 40.2 Mitter Known AF: Kown AF: angle lead ECG Device: ZoPatch 75±8<</td><td></td><td></td><td></td><td></td><td></td><td>Sequence: continuous, 14 days Biodata:</td><td></td><td>60%</td><td>3766</td><td>4.4 (3.8–5.1)</td></th<>	STROKESTOP II High-risk subgroup old Inclusion: NT-proBNP 215 sig1 Exclusion: Known AF: single lead ECG Device: Dohatch 72_±46 S8 2244 23 (1) ARC Exclusion: implantable PM/ICDIR, sina allegy Known AF: angle lead ECG Device: ZoPatch 73_±46 S8 23 (1) ARC Exclusion: implantable PM/ICDIR, sina allegy Known AF: angle lead ECG Device: ZoPatch 73_±46 S8 23 (1) Steminular tet al. 2018 ¹¹ General population based (all subscripes of a certim health care sommous). 2x14 days Biodita: 73_±470 41% 73 (1) 23 (1) Steminular tet al. 2018 ¹¹ General population based (all subscripes of a certim health care sommous). 2x14 days Biodita: 73_±470 41% 73 23 (1) Mitter Known AF: angle lead ECG Device: ZoPatch 75±8 48% 804 40.2 Mitter Known AF: angle lead ECG Device: ZoPatch 75±8 48% 804 40.2 Mitter Known AF: angle lead ECG Device: ZoPatch 75±8 48% 804 40.2 Mitter Known AF: angle lead ECG Device: ZoPatch 75±8 48% 804 40.2 Mitter Known AF: Kown AF: angle lead ECG Device: ZoPatch 75±8<						Sequence: continuous, 14 days Biodata:		60%	3766	4.4 (3.8–5.1)
excludedRooney et al. 2019 ³² Community based Region: USA Age: 275 years Inclusion:ARICExclusion: implantable PM/ICD/ILR, skin allergic Known AF:Steinhubl et al. 2018 ³³ General population based (all subscribers of a certain health caremSToPSGeneral population based (all subscribers of a certain health caremSToPSGeneral population based (all subscribers of a certain health caremSToPSGeneral population based (all subscribers of a certain health caremSToPSGeneral population based (communitie), Indusion:Exclusion: implantable PM/ICD, on OAC, known AF: excludedHeckbert et al. 2018 ³⁴ General population based (communitie), Region: USA Age: 2PRESA (substudy)18 years Inclusion: -Exclusion: skin allergy to tapefadhesivesMESA (substudy)General population based Region: USA Age: 2Apple Heart Study own analysis of porticipantsApple Watch owner Exclusion: -Known AF: excludedApple Heart Study own analysis of porticipantsApple Watch owner Exclusion: -Known AF:Apple Heart Study own analysis of porticipantsApple Watch owner Exclusion: -Known AF:Apple Heart Study own analysis of porticipantsApple Watch owner Exclusion: -Known AF:Apple Heart Study Design poperItubit cert al. 2019 ¹⁶ Apple Heart Study Design poperItubit device owner Exclusion: -Known AF:Apple Heart Study Design poperItubit device owner Exclusion: -Known AF:Approxipants of porticipants of porticipants of porticipantsInclusion: -Itubit device owner Exclusion: -Known AF:Apple Heart Study Design poperItubit device owne	Ronowy et al. 2019 ¹¹ conduction conduction AKC Exclusion: implantale PMCDULR, sixin allergi Known AF: single lead ECG Device: ZoPatch 73.2 ±16 8% 2.94 2.91 AKC Steinhubl et al. 2018 ¹¹ Cemeral population based (all subscribers of a certain health care Sequence continuous, 14 days Blodata: 73.7 ±7.0 41% 173 2.91 Steinhubl et al. 2018 ¹¹ Cemeral population based (all subscribers of a certain health care Sequence continuous, 14 days Blodata: 73.7 ±7.0 41% 173 2.91 MST oPS pain9 Region: USA Age: 2.75 years or 2.65 years + Female + 1 single lead ECG Device: ZoPatch 73.2 ±8 48% 804 40.2 MST oPS pain9 Region: USA Age: 2.75 years or 2.65 years + Female + 1 single lead ECG Device: ZoPatch 73.2 ±8 48% 804 40.2 MST oPS Cemeral population based flagon: USA Age: 2.75 years rolusion: Sequence continuous, 14 days Blodata: 73.2 ±8 48% 804 40.2 MSS (substrudy) 18 years inclusion: Exclusion: Sequence continuous, 14 days Blodata: 73.4 ±9.2 10.2 73.4 ±9.2 10.2 MSS (substrudy) 18 years inclusion: Sequence continuous, 14 days Blodata: 73.4 ±9.2 40.2				STROKESTOP II High-risk subgroup		single lead ECG Device: Novacor R-test 4				
Rooney et al. 2019Community based Region: USA Age: 275 years Inclusion:ARICExclusion: implantable PMI/CD/IIR, skin allergic Known AF: separatedSteinhubl et al. 2018 ¹³ General population based (all subscribers of a certain health care mSToPSMSToPSGeneral population based (all subscribers of a certain health care plan? Region: USA Age: 275 years vr \geq 65 years + Female + 1 comorbidity or \geq 55 years + Male + 1 comorbidity Inclusion: -Exclusion: implantable PMI/CD, on OAC, known AF: known AF. excluded Heckbert et al. 2018 ³⁴ Heckbert et al. 2018 ³⁴ General population based (all subscribers of a certain health care plan? Region: USA Age: 2 MSCA Age: 2 PMI/CD, on OAC, known AF: excluded ged \geq 5 yearsApple Heart Study own analysis of porticipantsAflutter Known AF: excluded aged \geq 5 yearsApple Heart Study own analysis of porticipantsApple Watch owner Exclusion: -Known AF: excluded aged \geq 5 yearsApple Heart Study own analysis of porticipantsApple Watch owner Exclusion: -Known AF: included aged \geq 5 yearsApple Heart Study OwnInclusion: Hawel smartphone owner Exclusion: -Known AF: included undysis of porticipants aged \geq 5 yearsApple Heart Study Design poperReneral population based Region: USA Age: 2 18 years included aged \geq 5 yearsApple Heart Study OwnApple Watch owner Exclusion: -Known AF: includedApple Heart Study Design poperReneral population based Region: USA Age: 2 2 years inclusion included ubbits et al. 2019 ¹⁶ Apple Vast Nown AF: excluded (AFIAFIUtter)Apple Vast Nown AF: excluded (AFIAFIUTED)	Rooney et al. 2019 ¹³ Community based Rejon: USA Age: 27 years Inclusion: Sequence continuous, 14 days Biodata 732.44 254 234 231 ARIC Exclusion: implantable PMUCDLR, stan allenge Known AF: single lead ECG Device: ZoPatch 732.44 231					excluded	evolution				
ARICExclusion: implantable PM/ICD/ILR, skin allergic Known AF: separatedSteinhubl et al. 2018 ¹³ General population based (all subscribers of a certain health care mSToPSSteinhubl et al. 2018 ¹⁴ General population based (all subscribers of a certain health care plan9 Region: USA Age: ≥ 75 years or ≥ 65 years + Female + 1mSToPSRevolution device (all subscribers of a certain health care plan9 Region: USA Age: ≥ 75 years or ≥ 65 years + Female + 1comorbidity or ≥ 55 years + Male + 1 comorbidity indusion: -Exclusion: implantable PM/ICD, on OAC, known AF: known AF excluded Perez et al. 2018 ¹⁴ General population based (a communities) Region: USA Age: \geq MBSA (substudy)Apple Heart Study own analysis of porticipantsApple Heart Study own analysis of porticipantsApple WilcD, on OAC, known AF: excluded aged ≥ 65 yearsApple Heart Study own analysis of porticipantsApple Watch owner Exclusion: -Known AF: excluded aged ≥ 65 yearsApple Watch owner Exclusion: -Known AF: included clubed udedApple Heart Study OwnRudes in 2019 ¹⁶ General population based Region: USA Age: ≥ 18 years funded aged ≥ 65 yearsApple Watch owner Exclusion: -Known AF: included clubed clubers et al. 2019 ¹⁶ Apple Heart Study Design poperRudes in Rautch owner Exclusion: -Known AF: included Clubers or OAC, implanted PM/ICDFIBIT Heart Study Design poperFibit device owner Exclusion: on OAC, implanted PM/ICDFIBIT Heart Study Design poperFibit device owner Exclusion: on OAC, implanted PM/ICD	ARC Exclusion: implantable PM/CD/ILK sin allergic Known AF: single lead ECC Device: ZioPatch 1739 29 (2) Steinhubl et al. 2018 ¹¹ General populationsaed (all subscribers of a certain health care Sequence continuous, 2x14 days Boddata: 737 ± 70 41% 1738 29 (2) Steinhubl et al. 2018 ¹¹ General populationsaed (all subscribers of a certain health care Sequence continuous, 2x14 days Boddata: 757 ± 70 41% 1738 29 (2) Matter Known AF: excluded Afluter Known AF: excluded Afluter Known AF: excluded 75 ± 8 48% 804 410 (2) MESA (abstudy) 18 years inclusion: Eccusion: sion allergy to tapeadhesives single lead ECC Device: ZioPatch 75 ± 8 48% 804 410 (2) Apple Heart Study own anolysis of pontiopion based (geon: USA Age: 218 years inclusion: Eccusion: sion allergy to tapeadhesives single lead ECC Device: ZioPatch 75 ± 8 48% 804 410 (2) Apple Heart Study own anolysis of pontiopion based Regon: USA Age: 218 years inclusion: Sequence: continuous Bodata: PFC ECC N/A 735 ± 8 804 410 (2) Apple Heart Study own anolysis of pontiopions based Regon: USA Age: 218 years inclusion: Sequence: continuous Bodata: PFC ECC N/A 736' 745' 245'/// 5'// 5'// 5'// 5'// 5'// 5'// 5'/				Rooney et al. 2019 ³²	Community based Region: USA Age:≥ 75 years Inclusion:	Sequence: continuous, 14 days Biodata:	79.2±4.6	58%	2244	2.5 (1.9–3.2)
spenratedSteinhubl et al. 2018'3General population based (all subscribers of a certain health care plan9 Region: USA Age: \geq 75 years or \geq 65 years + Female + 1mSToPSPain9 Region: USA Age: \geq 75 years or \geq 65 years + Female + 1comorbidity or \geq 55 years + Male + 1 comorbidity Indusion: - Exclusion: implantable PMICD, on OAC, known AF, known AF. excludedHeckbert et al. 2018'4General population based (communities) Region: USA Age: \geq MESA (substudy)Apple Heart Study own analysis of porticipants18 years Inclusion: - Exclusion: USA Age: \geq MESA (substudy)Apple Heart Study own analysis of porticipantsApple Watch owner Exclusion: - Known AF: excluded aged \geq 65 yearsApple Heart Study own analysis of porticipantsApple Watch owner Exclusion: - Known AF: excluded aged \geq 55 yearsPre-MAFA II (Huawei Heart Study) ownInclusion: USA Age: \geq 18 years Inclusion: analysis of porticipantsApple Heart Study own analysis of porticipantsApple Watch owner Exclusion: - Known AF: excluded aged \geq 55 yearsApple Heart Study Design poperInclusion: Hawei smartphone owner Exclusion: - Known AF: included Chereal population based Region: USA Age: \geq 28 years inclusion: HTBIT Heart Study Design poperFITBIT Heart Study Design poperFitbit device owner Exclusion: on OAC, implanted PMICD Known AF: excluded (AFIAFlutter)	Steinhuble te al. 2019 ⁴ Ceneral population based (all subscribers of a certain health care Sequence continuous, 2×14 days Biodata: 737 ± 70 41% 1738 29 (2 mSToPS pain9 Regoru USA Agez S 7 years ver 26 5 years + Frande + 1 single lead ECG Device: ZloPatch 75 ± 8 48% 804 40 (2 Feduciart implantable PWICD: on OAC, Icrow AT, Innow - Exclusion: implantable PWICD: on OAC, Icrow AT, Innow 75 ± 8 48% 804 40 (2 MESA (substudy) 13 years industor: Precoded Prece z et al. 2019 ⁴ 57 ± 20 (4 days Biodata: 75 ± 8 48% 804 40 (2 Apple Vactor General population based (communities) Region: USA Age: 2 (8 years industor: FCG Device: ZloPatch 75 ± 8 48% 804 40 (2 Apple Vactor Room AF: excluded Non AF: excluded Non Accore: ZloPatch 75 ± 8 48% 804 40 (2 Apple Heart Study oun anolysis of participants Apple Heart Study oun anolysis of participants Sequence continuous Biodata: PC + ECG NA 42% 246/26 246/26 246/26 246/26 246/26 246/26 246/26 246/26 246/26 246/26 246/26 246/26 246/26 246/26 24/26<				ARIC	Exclusion: implantable PM/ICD/ILR, skin allergic Known AF:	single lead ECG Device: ZioPatch				
Steinhubl et al. 2018'3General population based (all subscribers of a certain health care mSToPSDan9 Region: USA Age: ≥ 75 years or ≥ 65 years + Fermale + 1mSToPSplan9 Region: USA Age: ≥ 75 years or ≥ 65 years + Fermale + 1comorbidity or ≥ 55 years + Male + 1 comorbidity Indusion: -Exclusion: implantable PMICD, on OAC, known AT, known Affutter Known AF: excluded Perez et al. 2018'4Affutter Known AF: excluded Perez et al. 2019'5General population based (6 communities) Region: USA Age: \geq MBSA (substudy)Apple Heart Study own analysis of porticipantsApple Watch owner Exclusion: skin allergy to tapefadhesives Known AF: excluded aged ≥ 65 yearsApple Heart Study own analysis of porticipantsApple Watch owner Exclusion: -Known AF: excluded aged ≥ 65 yearsApple Heart Study own analysis of porticipantsApple Watch owner Exclusion: -Known AF: included aged ≥ 65 yearsPre-MAFA II (Huawei Heart Study) ownRouval atthone owner Exclusion: -Known AF: included Clubitz et al. 2013'6Apple Matt Study Design poperCeneral population based Region: USA Age: ≥ 20 years inclusion: FITBIT Heart Study Design poperFITBIT Heart Study Design poperFitbit device owner Exclusion: on OAC, implanted PMICD Known AF: excluded (AFIAFlutter)	Steinhold et al. 2018 ³⁴ General population based (all subscribers of a certain health care Sequence continuous, 2x 14 days Blodta: 73.2 \pm 70 41% 1738 29 (2) mSToPS pan9 Region: USA Age: 25 years v = 26 years + Female + 1 single ead ECG Device: ZoPatch 73 \pm 8 49% 400 (2) Feddbert et al. 2018 ⁴⁴ connobidity or 25 years + Male + 1 connobidity Indision: Ecdusion: ISA Age: 25 years + Male + 1 connobidity Indision: 54 \pm 8 48% 804 410 (2) Feddbert et al. 2018 ⁴⁴ General population based (6 communities) Region: USA Age: 2 sequence: continuous; 14 days Blodta: 75 \pm 8 48% 804 410 (2) Presz et al. 2019 ⁴⁵ General population based (6 communities) Region: USA Age: 2 sequence: continuous; 14 days Blodta: 75 \pm 8 48% 804 410 (2) Apple Heart Study on 18 years Inclusion: E-culusion: USA Age: 2 sequence: continuous; 14 days Blodta: 75 \pm 8 804 410 (2) Apple Heart Study on 18 years Inclusion: E-culusion: USA Age: 2 sequence: continuous; 14 days Blodta: 75 \pm 8 804 410 (2) Apple Heart Study on 18 years Inclusion: E-culusion: E-cul					separated					
mSToPSplan9 Region USA Age: \geq 75 years or \geq 65 years + Female + 1comorbidity or \geq 55 years + Male + 1 comorbidity Indusion:-Exclusion: implantable PM/ICD, on OAC, known AT, knownHeckbert et al. 2018*General population based (communities) Region: USA Age: \geq MESA (substudy)18 years Inclusion: excludedPerez et al. 2019*General population based Region: USA Age: \geq MESA (substudy)18 years Inclusion: excludedPerez et al. 2019*General population based Region: USA Age: \geq MSPIE Heart Study own analysis of porticipantsApple Heart Study own analysis of porticipantsApple Heart Study own analysis of porticipantsApple Heart Study own analysis of porticipantsRow AFERue MAFA II (Huawei Heart Study) ownReneral population based Region: USA Age: \geq 18 yearsRue AFA II (Huawei Heart Study) ownRue AFA II (Huawei Heart Study) ownRue AFE AFA II (Huawei Heart Study) ownRue Aff All (Huawei Heart Study) ownRue Aff All (Huawei Heart Study) Design poperFITBIT Heart Study Design poperFITBIT Heart Study Design poperFITBIT Heart Study Design poperFITBIT Heart Study Design poperFitbit device owner Exclusion: on OAC, implanted PM/ICDKnown AF: excluded (AFIAFlutter)	mSTGPS pan9 Region USA Agez 25 years voit 65 years + Famale + 1 single lead ECG Device. ZoPatch comorbidity or 255 years + Male + 1 comorbidity inclusion: Exclusion: implantable PW/ICD, on OAC, known AT, known Affutter Known AT, known Affutter Known AT, known Heckbert et al. 2018** General population based (6 communities) Region: USA Agez 2 Sequence: continuous, 14 days Biodata: 75 ± 8 894 40 (2 MESA (substudy) 18 years inclusion: Exclusion: sin allergy to tape/adhesives single lead ECG Device: ZoPatch 75 ± 8 894 40 (2 Apple Heart Study own on/ysi of pontiopentsed Region: USA Age: 2 18 years inclusion: and/ysis of pontiopents aged 2 55 years Apple Watch owner Exclusion: Known AF: excluded 75 ± 8 894 40 (2 Apple Heart Study own onlysis of pontiopentsed Region: USA Age: 2 18 years inclusion: For warf Requence: continuous Biodata: PFG ECG N/A 725 ± 8 31 (2) Pre-MATA II (Huawei Heart Study own Inclusion: Known AF: inclusion: Known AF: Hawei Natch or Honor N/A 725 ± 8 3419 28 (2) Region Edition Region: USA Age: 2 18 years Sequence: continuous Biodata: PFG ECG N/A 725 ± 8 24 (2) 24 (2) Apple Heart Study own Inclusion: Fourbus Richarts PCA N/A 13 (2) 24 (2)				833	General population based (all subscribers of a certain health care $\frac{1}{2}$	bequence: continuous, 2×14 days Biodata:	73.7 ± 7.0	41%	1738	2.9 (2.2–3.8)
comorbidity or \geq 55 years + Male + 1 comorbidity Inclusion: -Exclusion: implantable PM/ICD, on OAC, known AT, known Heckbert et al. 2018 ³⁴ Heckbert et al. 2018 ³⁴ General population based (6 communities) Region: USA Age: \geq MESA (substudy) MESA (substudy) 18 years Inclusion: -Exclusion: USA Age: \geq MESA (substudy) Preze et al. 2019 ¹⁵ General population based (6 communities) Region: USA Age: \geq MSA Apple Heart Study own analysis of participants Apple Heart Study own analysis of participants Apple Watch owner Exclusion: -Known AF: included oged \geq 65 years Pre-MAFA II (Huawei Heart Study) own analysis of participants Apple Watch owner Exclusion: -Known AF: included Pre-MAFA II (Huawei Heart Study) own analysis of participants aged \geq 65 years General population based Region: USA Age: \geq 18 years included Pre-MAFA II (Huawei Heart Study) own analysis of participants aged \geq 65 years Lubhiz et al. 201 ³⁰ General population based Region: USA Age: \geq 22 years Inclusion: FITBIT Heart Study Design paper FITBIT Heart Study Design paper Fitbit device owner Exclusion: on OAC, implanted PM/ICD	comorbidity or ≥ 55 years +Male +1 comorbidity inclusion: Exclusion: implantable PM/ICD, on OAC, known AT, known Fxclusion: implantable PM/ICD, on OAC, known AT, known Affutter Known AF, known Affutter Known AF, courbid Affutter Known AF, known MESA (substudy) T8 years inclusion: excluded 75±8 48% 804 40 (2 MESA (substudy) T8 years inclusion: excluded single lead ECC Device: ZioPatch 75±8 48% 804 40 (2 Apple Heart Study own molysis of participants Apple Watch owner Exclusion: Known AF: included patch Device: Apple Watch NIA 42% 242% 24.02% 31 (2 Apple Heart Study own molysis of participants Apple Watch owner Exclusion: Known AF: included patch Device: Apple Watch NIA 42% 24.02% 32 (2 28 (2 Apple Heart Study own molysis of participants Apple Watch owner Exclusion: Known AF: included patch Device: Apple Watch NIA 42% 24.02% 24 (2 24 (2 28 (2 28 (2 28 (2 28 (2 28 (2 28 (2 28 (2 28 (2 28 (2 28 (2 28 (2 28 (2 28 (2 28 (2 28 (2 28 (2 28 (2 28 (2 28 (2				mSToPS	plan9 Region: USA Age: ≥ 75 years or ≥ 65 years + Female + 1	single lead ECG Device: ZioPatch				
Exclusion: implantable PM/ICD, on OAC, known AT, known Aflutter Known AF: excludedHeckbert et al. 2018 ³⁴ General population based (6 communities) Region: USA Age: 2 MESA (substudy)MESA (substudy)18 years inclusion: -Exclusion: Skin allergy to tape'adhesives Known AF: excludedPrez et al. 2019 ¹⁵ General population based Region: USA Age: \geq 18 years inclusion: dogd \geq 65 yearsApple Heart Study own analysis of participantsApple Watch owner Exclusion: -Known AF: excluded oged \geq 65 yearsPre-MAFA II (Huawei Heart Study) ownGeneral population based Region: China Age: \geq 18 years rouched oged \geq 65 yearsPre-MAFA II (Huawei Heart Study) ownInclusion: Huawei smartphone owner Exclusion: -Known AF: included Lubitz et al. 201 ¹²⁰ FTBIT Heart Study Design poperFtibit device owner Exclusion: OAC, implanted PM/ICD Known AF: excluded	Feduatoric mplantable PM/ICD, on OAC, known AT, known Aftatier Known AF, excluded MEckbert et al. 2018* General population based (6 communities) Region: USA Age: 2 Sequence: continuous, 14 days Biodata. 75 \pm 8 48% 804 40 (2) MESA (substudy) 18 years inclusion: sixin allergy to tape/adhesives single lead ECG Device: ZloPatch 75 \pm 8 48% 804 40 (2) Apple Heart Study own onoysis of partipotion based Region: USA Age: 2 18 years inclusion: sixin allergy to tape/adhesives single lead ECG Device: ZloPatch NIA 42% 246'26 31 (2) Apple Heart Study own onoysis of partipotion based Region: USA Age: 2 18 years included patch Device Apple Watch NIA 42% 246'26 31 (2) Apple Heart Study own onoysis of partipotion based Region: USA Age: 2 18 years included patch Device: Apple Watch NIA 42% 246'26 31 (2) Apple Heart Study own onoysis of partipotion based Region: USA Age: 2 18 years included patch Device: Apple Watch NIA 42% 246'26 31 (2) Apple Heart Study own onolysis of partipotion based Region: USA Age: 2 18 years included patch Device: Apple Watch NIA 43% 246'26 32 (2) Apple Heart Study Devicippores oge/2 65 yeeral ceneral population bas					comorbidity or \ge 55 years + Male + 1 comorbidity Inclusion:					
Affutter Known AF: excluded Heckbert et al. 2018 ¹⁴ Affutter Known AF: excluded Begion: USA Age: \geq MESA (substudy)MESA (substudy)General population based (6 communities) Region: USA Age: \geq Known AF: excludedPreze et al. 2019 ¹⁵ General population based Region: USA Age: \geq 18 years Inclusion: Apple Heart Study own analysis of participantsApple Heart Study own analysis of participantsApple Watch owner Exclusion: -Known AF: included oged \geq 65 yearsPre-MAFA II (Huawei Heart Study) ownGeneral population based Region: China Age: \geq 18 years four et al. 2019 ¹⁶ Pre-MAFA II (Huawei Heart Study) ownInclusion: Huawei smartphone owner Exclusion: -Known AF: included Lubliz et al. 2011 ²⁰ Fre-MAFA II (Huawei Heart Study) Design poperGeneral population based Region: China Age: \geq 21 years fublit et al. 2011 ²⁰ FITBIT Heart Study Design poperFitbit device owner Exclusion: on OAC, implanted PMICD Known AF: excluded (AFIAFlutter)	Aftuter Known AF: excluded Heckbert et al. 2018 ³⁴ General population based (6 communities) Region: USA Age: 2 Sequence: continuous, 14 days Biodata. 75 ± 8 48% 804 40.(2) MESA (ubstudy) 18 years Inclusion: Exclusion: skin allegy to tape/adhesives single lead ECG Device: ZloPatch 75 ± 8 48% 804 40.(2) Perez et al. 2019 ¹⁵ General population based Region: USA Age: 2 18 years Inclusion: Sequence: continuous Biodata: PFG FECG N/A 42% ^c 246.26 31.(2) Apple Heart Study own analysis of participants Apple Watch owner Exclusion: Known AF: Included patch Device: Apple Watch N/A 42% ^c 246.26 31.(2) Apple Heart Study own analysis of participants Apple Watch owner Exclusion: Known AF: Included patch Device: Apple Watch N/A 13% ^c 246.26 31.(2) Apple Heart Study own analysis of participants Apple Watch owner Exclusion: Known AF: Included patch Device: Apple Watch N/A 13% ^c 246.26 31.(2) Amalysis of participants Apple Watch owner Exclusion: Known AF: Included Bard M/A 13% ^c 34.(2) 24.(2) 24.(2) 24.(2) 24.(2) 24.(2) 24.(2) 24.(2) 24.(2)<					-Exclusion: implantable PM/ICD, on OAC, known AT, known					
Heckbert et al. 2018*4General population based (6 communities) Region: USA Age: \geq MESA (substudy)18 years Inclusion: -Exclusion: skin allergy to tape/adhesives Known AF: excludedPerez et al. 2019*5General population based Region: USA Age: \geq 18 years Inclusion: Apple Heart Study own analysis of participantsApple Watch owner Exclusion: -Known AF: included oged \geq 65 yearsApple Heart Study own analysis of participantsApple Watch owner Exclusion: -Known AF: included oged \geq 65 yearsGeneral population based Region: China Age: \geq 18 years nucledPre-MAFA II (Huawei Heart Study) ownInclusion: Huawei smartphone owner Exclusion: -Known AF: included Lubliz et al. 2011*0General population based Region: China Age: \geq 18 years randysis of participants aged \geq 65 yearsPre-MAFA II (Huawei Heart Study) ownInclusion: Huawei smartphone owner Exclusion: -Known AF: included Lubliz et al. 2013*0General population based Region: China Age: \geq 21 years Inclusion: HTBIT Heart Study Design poperFITBIT Heart Study Design poperFitbit device owner Exclusion: on OAC, implanted PMI/ICDKnown AF: excluded (AFIAFlutter)	Heckbert et al. 2018 ⁴ General population based (6 communites) Region: USA Age: 2 Sequence continuous, 14 days Blodata. 75 \pm 8 48% 804 4.0 (2) MESA (substudy) 18 years Inclusion: skin allergy to tape/adhesives single lead ECG Device: ZoPatch 7 \pm 8 48% 804 4.0 (2) Perez et al. 2019 ¹⁵ General population based Region: USA Age: 2 18 years Inclusion: single lead ECG Device: ZoPatch NIA 42% 246.26 3.1 (2) Apple Heart Study ow analysis of participants Apple Watch owner Exclusion: Known AF: included patch Device: Apple Watch NIA 42% 246.26 3.1 (2) Pre-MAFA II (Huawei Heart Study) own analysis of participants Apple Watch on Honor NIA 13%' 3419 2.8 (2) Pre-MAFA II (Huawei Heart Study) own huawei smarthhone owner Exclusion: -Known AF: Huawei Watch on Honor NIA 13%' 3419 2.8 (2) Pre-MAFA II (Huawei Heart Study) own nclusion: Huawei smarthhone owner Exclusion: -Known AF: Huawei Watch on Honor NIA 13%' 3419 2.8 (2) Pre-MAFA II (Huawei Heart Study) own Induced Band NIA 13%' 246.26 Analysis orgoing/unpublished Iubitz et al. 2019 ¹⁶ G					Aflutter Known AF: excluded					
$\begin{split} \mbox{MESA} (substudy) & 18 \mbox{years Inclusion: -Exclusion: skin allergy to tape/adhesives} \\ & \mbox{Perez et al. 2019}^{15} & \mbox{Rinown AF: excluded} \\ & \mbox{Perez et al. 2019}^{15} & \mbox{General population based Region: USA Age: 2 18 years Inclusion:} \\ & \mbox{Apple Heart Study own analysis of participants} & \mbox{Apple Watch owner Exclusion: -Known AF: included} \\ & \mbox{aged} \geq \delta 5 \mbox{years} & \mbox{Apple Watch owner Exclusion: -Known AF: included} \\ & \mbox{aged} \geq \delta 5 \mbox{years} & \mbox{Apple Watch owner Exclusion: -Known AF: included} \\ & \mbox{aged} \geq \delta 5 \mbox{years} & \mbox{Apple Watch owner Exclusion: -Known AF: included} \\ & \mbox{aged} \geq \delta 5 \mbox{years} & \mbox{Apple Watch owner Exclusion: -Known AF: included} \\ & \mbox{Apple Heart Study Design poper} & \mbox{Apple Watch owner Exclusion: -Known AF: included} \\ & \mbox{Apple Heart Study Design poper} & \mbox{Fibit device owner Exclusion: 0 OAC, implanted PM/ICD} \\ & \mbox{Known AF: excluded (AF/AFlutter)} \\ & \mbox{Apple Heart Study Design poper} & \mbox{Apple OAC, implanted PM/ICD} \\ & \mbox{Apple NITCH} \\ & \mbox{Apple Study Design poper} & \mbox{Apple Study Design poper} \\ & $	MESA (substudy)18 years Inclusion: -Exclusion: skin allergy to tape/adhesivessingle lead ECG Device: ZioPatch $Freez et al. 2019^{15}$ General population based Region: USA Age: ≥ 18 years Inclusion: Sequence: continuous Biodata: PPG + ECGN/A $42\%^{\circ}$ 24626 3.1 (2)Apple Heart Study <i>own analysis of participants</i> Apple Watch owner Exclusion: -Known AF: includedpatch Device: Apple Watch $13\%^{\circ}$ 24626 3.1 (2)Apple Heart Study <i>own analysis of participants</i> Apple Watch owner Exclusion: -Known AF: includedpatch Device: Apple Watch $13\%^{\circ}$ 24626 Apple Heart Study <i>own analysis of participants</i> Apple Watch owner Exclusion: -Known AF: includedpatch Device: Apple Watch 3419 2.8 (2)Pre-MAFA II (Huavei Heart Study) <i>own</i> Inclusion: Huavei smartphone owner Exclusion: -Known AF: Huavei Vatch or HonorN/A $13\%^{\circ}$ 3419 2.8 (2)Unbitz et al. 2019 ¹⁶ General population based Region: USA Age: ≥ 22 years Inclusion: Biodata: PFG FECGN/A $13\%^{\circ}$ 3419 2.8 (2)Unbitz et al. 2012 ¹⁰ General population based Region: USA Age: ≥ 22 years Inclusion: Sequence: continuous Biodata: PFG + ECGAnalysis orgoing/unpublishedHTBIT Heart Study Design poperFtbit device owner Exclusion: on OAC, implanted PMI/CDAt versa Lite, Versa 2, versa 3, sense,Analysis orgoing/unpublishedHTBIT Heart Study Design poperFtbit device owner Exclusion: on OAC, implanted PMI/CDAt versa Lite, Versa 2, versa 3, sense,Analysis orgoing/unpublishedHTBIT Heart Study Design poperFtbit device owner Exclusion: OAC, implanted PMI/CD					General population based (6 communities) Region: USA Age:≥	Sequence: continuous, 14 days Biodata:	75±8	48%	804	4.0 (2.7–5.6)
Known AF: excludedPerez et al. 2019 ¹⁵ General population based Region: USA Age: \geq 18 years Inclusion:Apple Heart Study own analysis of participantsApple Watch owner Exclusion: -Known AF: includedaged \geq 65 yearsGeneral population based Region: China Age: \geq 18 yearsGuo et al. 2019 ¹⁶ General population based Region: China Age: \geq 18 yearsPre-MAFA II (Huawei Heart Study) ownInclusion: Huawei smartphone owner Exclusion -Known AF:andysis of participants aged \geq 65 yearsincludedUubitz et al. 2011 ²⁰ General population based Region: USA Age: \geq 22 years Inclusion:FTBIT Heart Study Design paperFitbit device owner Exclusion: on OAC, implanted PM/ICDFTBIT Heart Study Design paperFitbit device owner Exclusion: on OAC, implanted PM/ICD	Ferez et al. 2019 ¹⁵ Ceneral population based Region: USA Age: 218 years inclusion: Sequence: continuous Biodata: PFG + ECG N/A 42% ⁻ 2462.6 3.1 (2) Apple Heart Study own anolysis of participants Apple Watch owner Exclusion: Known AF: included patch Device: Apple Watch 747.9 2462.6 3.1 (2) Apple Heart Study own anolysis of participants Apple Watch owner Exclusion: Known AF: included patch Device: Apple Watch 747.9 2462.6 3.1 (2) Pre-MAFA II (Huavei Heart Study) own Inclusion: Huavei Smartphone owner Exclusion: Known AF: Huavei Watch or Honor 13% ⁴ 3419 2.8 (2) Pre-MAFA II (Huavei Heart Study) own Inclusion: Huavei Smartphone owner Exclusion: Known AF: Huavei Watch or Honor NiAt 13% ⁴ 3419 2.8 (2) Iubitz et al. 201 ¹⁰ General population based Region: USA Age: 2.2 years inclusion: Biodata: PFG + ECG Analysis orgoing/unpublished Iubitz et al. 201 ¹⁰ General population based Region: USA Age: 2.2 years inclusion: Sequence: continuous Biodata: PFG + ECG Analysis orgoing/unpublished Iubitz et al. 201 ¹⁰ Fibit device owner Exclusion: O.O.C. implanted PMI/CD Patch Device: Fibit honic. Charge 3.C harge FITBIT Heart Study Desgip poper Fibit device owner Exclusion: on O.O.C. implanted PMI/CD Patch Device: Fibit honic. Charge 3.C harge				MESA (substudy)	18 years Inclusion: -Exclusion: skin allergy to tape/adhesives	single lead ECG Device: ZioPatch				
Perezet al. 201915General population based Region: US A Age: \geq 18 years Inclusion:Apple Heart Study own analysis of participantsApple Watch owner Exclusion: -Known AF: included aged \geq 65 yearsGeneral population based Region: China Age: \geq 18 years Guo et al. 2019 ¹⁶ Pre-MAFA II (Huawei Heart Study) ownInclusion: Huawei smartphone owner Exclusion -Known AF: includedPre-MAFA II (Huawei Heart Study) ownInclusion: Huawei smartphone owner Exclusion -Known AF: includedOracle 265 yearsincludedIubitz et al. 2021 ²⁰ General population based Region: US Age: \geq 22 years Inclusion: HTBIT Heart Study Design paperFITBIT Heart Study Design paperFitbit device owner Exclusion: on OAC, implanted PM/ICD Known AF: excluded (AFIAFlutter)	Prez et al. 2019 ¹⁵ General population based Region: USA Age: 218 years Included Rich Device: Apple Watch 246.26 3.1 (2) Apple Heart Study own analysis of participants Apple Watch owner Exclusion: -Known AF: included patch Device: Apple Watch 246.26 3.1 (2) aged 2 65 years General population based Region: China Age: 218 years Sequence: continuous Blodata: PPG Device: NIA 13% ^c 3419 2.8 (2) Pre-MAFA II (Huawei Heart Study) own Inclusion: Huawei smartphone owner Exclusion: -Known AF: Huawei Watch or Honor NIA 13% ^c 3419 2.8 (2) Pre-MAFA II (Huawei Heart Study) own Inclusion: Huawei smartphone owner Exclusion: -Known AF: Huawei Watch or Honor Watch or Honor Match or Honor 2.8 (2) Uubitz et al. 2021 ⁴⁰ General population based Region: USA Age: 2.2 years Inclusion: Sequence: continuous Blodata: PFG + ECG Analysis orgoing/unpublished HTBIT Heart Study Desgin poper Ftbit device owner Exclusion: on OAC, implanted PMI/CD patch Device: Ftbit lonic. Charge 3. Charge Analysis orgoing/unpublished FITBIT Heart Study Desgin poper Ftbit device owner Exclusion: on OAC, implanted PMI/CD patch Device: Acris Line, Versa 2. Versa 3. Sense, Analysis orgoing/unpublished FITBIT Heart Study Desgin poper Ftbit device owner Exclusion: on OAC, implanted PMI/CD					Known AF: excluded					
Apple Watch owner Exclusion: -Known AF: included General population based Region: China Age: ≥ 18 years Inclusion: Huawei smartphone owner Exclusion: -Known AF: included General population based Region: USA Age: ≥ 22 years Inclusion: Fitbit device owner Exclusion: on OAC, implanted PM/ICD Known AF: excluded (AF/AFlutter)	Apple Watch owner Exclusion: -Known AF: included patch Device: Apple Watch 28 (2) General population based Region: China Age: ≥ 18 years Sequence: continuous Biodata: PPG Device: N/A 13% 3419 28 (2) Inclusion: Huawei smartphone owner Exclusion: -Known AF: Huawei Watch or Honor NiA 13% 3419 28 (2) Included Each Band Band Analysis ongoing/unpublished General population based Region: USA Age: ≥ 22 years Inclusion: Sequence: continuous Biodata: PPG + ECG Analysis ongoing/unpublished Fibt device owner Exclusion: on OAC, implanted PM/ICD patch Device: Fibth Ionic, Charge 3, Charge Analysis ongoing/unpublished Known AF: excluded (AFIAFlutter) 4, Versa, Versa Lite, Versa 2, Versa 3, Sense, Inspire HR, Inspire 2			PPG	Perez et al. 2019 ¹⁵	General population based Region: USA Age: \geq 18 years Inclusion: :	Sequence: continuous Biodata: PPG + ECG			24 626	3.1 (2.9–3.3) ^a
General population based Region: China Age: ≥ 18 years Inclusion: Huawei smartphone owner Exclusion: -Known AF: included General population based Region: USA Age: ≥ 22 years Inclusion: Fitbit device owner Exclusion: on OAC, implanted PM/ICD Known AF: excluded (AF/AFlutter)	General population based Region: China Age: ≥ 18 years Sequence: continuous Biodata: PFG Device: N/A 13% 3419 28 (2) Inclusion: Huawei smartphone owner Exclusion: -Known AF: Huawei Watch or Honor Watch or Honor 13% 3419 28 (2) Inclusion: Huawei smartphone owner Exclusion: -Known AF: Huawei Watch or Honor Watch or Honor Match or Honor included Band Band Band Analysis ongoing/unpublished General population based Region: USA Age: >22 years Inclusion: Sequence: continuous Biodata: PFG + ECG Analysis ongoing/unpublished Fitbit device owner Exclusion: on OAC, implanted PM/ICD patch Device: Fitbit lonic, Charge 3, Charge Analysis ongoing/unpublished Known AF: excluded (AF/AFlutter) 4, Versa, Lite, Versa 1, versa, 2, versa 3, Sense, Inspire HR, Inspire 2			Ą	ople Heart Study own analysis of participants		patch Device: Apple Watch				
General population based Region: China Age: ≥ 18 years Inclusion: Huawei smartphone owner Exclusion: -Known AF: included General population based Region: USA Age: ≥ 22 years Inclusion: Fitbit device owner Exclusion: on OAC, implanted PM/ICD Known AF: excluded (AF/AFlutter)	General population based Region: China Age: ≥ 18 years Sequence: continuous Biodata: PFG Device: N/A 13% ^c 3419 28 (2) Inclusion: Huawei smartphone owner Exclusion: -Known AF: Huawei Watch or Honor Watch or Honor 3419 28 (2) Included Band Band Band Analysis ongoing/unpublished Fitbit device owner Exclusion: USA Age: ≥ 22 years Inclusion: Sequence: continuous Biodata: PFG + ECG Analysis ongoing/unpublished Fitbit device owner Exclusion: on OAC, implanted PM/ICD patch Device: Fitbit lonic, Charge 3, Charge Analysis ongoing/unpublished Known AF: excluded (AF/AFlutter) 4, Versa, Versa Lite, Versa 2, Versa 3, Sense, Inspire HR, Inspire 2				aged≥ 65 years						
Inclusion: Huawei smartphone owner Exclusion: -Known AF. included General population based Region: USA Age: 2 22 years Inclusion: Fitbit device owner Exclusion: on OAC, implanted PM/ICD Known AF. excluded (AF/AFlutter)	Included The and the included Band AF: Huawei Watch or Honor Watch or Honor included included Band Included Area: 22 years Inclusion: Sequence: continuous Biodata: PPG+ECG Analysis ongoing/unpublished Fitbit device owner Exclusion: on OAC, implanted PM/ICD patch Device: Fitbit Ionic, Charge 3, Charge Known AF: excluded (AF/AFlutter) 4, Versa Lite, Versa 2, Versa 3, Sense, Inspire HR, Inspire 4, Inspire 2				Guo et al. 2019 ¹⁶		equence: continuous Biodata: PPG Device:		13% ^c	3419	2.8 (2.3–3.4)
≥ 65 years included ²⁰ General population based Region: USA Age: ≥ 22 years inclusion: gn poper Ftibit device owner Exclusion: on OAC, implanted PM/ICD Known AF: excluded (AF/AFlutter)	2.65 years included Band 2.0 General population based Region: USA Age: 22 years Inclusion: Sequence: continuous Biodata: PPG + ECG Analysis ongoing/unpublished 20 General population based Region: USA Age: 22 years Inclusion: Sequence: continuous Biodata: PPG + ECG Analysis ongoing/unpublished 20 Fitbit device owner Exclusion: on OAC, implanted PM/ICD patch Device: Fitbit Ionic, Charge 3, Charge Analysis ongoing/unpublished 21 After Age After Age After Age After Age 22 Fitbit device owner Exclusion: on OAC, implanted PM/ICD patch Device: Fitbit Ionic, Charge 3, Charge Analysis ongoing/unpublished 23 Fitbit device owner Excluded (AFAFlutter) 4, Versa, Versa 1, Versa 2, Versa 3, Sense, Inspire 4, Inspire 2 Inspire H, Inspire 2				Pre-MAFA II (Huawei Heart Study) own		Huawei Watch or Honor Watch or Honor				
General population based Region: USA Age: ≥ 22 years Inclusion: Fitbit device owner Exclusion: on OAC, implanted PMICD Known AF: excluded (AF/AFlutter)	General population based Region: USA Age: ≥ 22 years inclusion: Sequence: continuous Biodata: PPG + ECG Analysis ongoing/unpublished Fitbit device owner Exclusion: on OAC, implanted PM/ICD patch Device: Fitbit Ionic, Charge 3, Charge Known AF: excluded (AF/AFlutter) 4, Versa, Versa Lite, Versa 2, Versa 3, Sense, Inspire HR, Inspire 2				analysis of participants aged ≥ 65 years	included	Band				
Fitbit device owner Exclusion: on OAC, implanted PM/ICD Known AF: excluded (AF/AFlutter)	Fitbit device owner Exclusion: on OAC, implanted PMI/ICD patch Device: Fitbit lonic, Charge 3, Charge Known AF: excluded (AF/AFlutter) 4, Versa, Versa Lite, Versa 2, Versa 3, Sense, Inspire 2					General population based Region: USA Age: \geq 22 years Inclusion: :	Sequence: continuous Biodata: PPG + ECG		Analysis ongoin	g/unpublisł	hed
	4, Versa, Versa Lite, Versa 2, Versa 3, Sense, Inspire HR, Inspire 2				FITBIT Heart Study Design paper		atch Device: Fitbit Ionic, Charge 3, Charge	0			
hspire 18. Inspire 2							i, Versa, Versa Lite, Versa 2, Versa 3, Sense,				
							Inspire HR, Inspire 2				

Guida Designation Foundation Designation Resumption Resumptio										
International Interna International International	Study	Monitoring	Technique	Author, study acronym subgroup/own analysis	Population		Mean age (+/- Std.)	Female (%)		Atrial rhythmia IF (%)
Image: Single	-	intermittent monitoring	single lead ECG	Berge et al. 2018 ³⁵ ACE1950 Follow-Up Ghazal et al. 2020 ³⁶	Community based Region: Sweden Age: 65 years Inclusion: ≥ 1 of HT, DM, HF, ST/TIA, VD Exclusion: -Known AF: excluded Community based Region: Stockholm regional, Sweden Age: ≥	Sequence: intermittent, 2 × daily, 14 days Biodata: single lead ECG Device: Zenicor Sequence: intermittent, 3 × daily, 14 days	:	44% 61%	1510 1010	0.9 (0.5–1.5) 2.7 (1.8–3.9)
House and the sected and the s				Halcox et al. 2017 ³⁷ REHEARSE.AF		Biodata: single lead ECG Device: Zenicor Sequence: intermittent, 2× weekly, 1 year Biodata: single lead ECG Device: AliveCor		52%	500	3.4 (2.0–5.4)
Serventery at 3.005 ⁴ Contrain polyation band Region Stotobin +Hullind condy, Sequence intermittin 1,3 x 44,14 kg, 14 kg, 15 NA 556 657 are in the intermitting of the intermitting cond, the intermed Region 3 Danie Sequence intermitting cond, the intermitting cond, the intermed Region 3 Danie Sequence intermitting cond, the intermed Region 3 Danie Secuence Region 7 Danie Secuence Region 7 Danie Secuence Region 7 Danie Secuence					PMICD Known AF: excluded					
one indef EC Contact is prevened form kit Region: J Darie I Servers is core ore parent: 0, request 60 (1) 50 (2) 71 (2) Indep and EC Predence on OCL Ione care or Mark is many bone kit Region: J Darie I Da				Svennberg et al. 2015 ³⁸ STROKESTOP (screening results)	General population based Region: Stockholm + Halland county, Sweden Age: 75 or 76 years old Inclusion: -Exclusion: -Known AF: separate	Sequence: intermittent, 2 × dally, 14 days Biodata: single lead ECG Device: Zenicor		55%	6507	3.8 (3.3-4.3)
addition Factor cat at 2024 ⁴ Communy based, at <i>A</i> -averess campaign ymposums Sequence once per partent. 30 Bodus: 74.45.0 24.45.0 <td< td=""><td></td><td>олсе</td><td>single lead ECG</td><td>Poulsen et al. 2022³⁹</td><td>Community based, at preventive home visits Region: 3 Danish municipals Age: 2.65 years Inclusion: understanding Danish Exclusion: on OAC, home care or living in nursing home Known AF: excluded</td><td>Sequence: once per patient (2 repeated neasures) Biodata: single lead ECG Device: Zenicor</td><td></td><td>56%</td><td>477</td><td>1.5 (0.6–3)</td></td<>		олсе	single lead ECG	Poulsen et al. 2022 ³⁹	Community based, at preventive home visits Region: 3 Danish municipals Age: 2.65 years Inclusion: understanding Danish Exclusion: on OAC, home care or living in nursing home Known AF: excluded	Sequence: once per patient (2 repeated neasures) Biodata: single lead ECG Device: Zenicor		56%	477	1.5 (0.6–3)
One, of the constant of the def ECG bener, three is 1200 ⁴¹ Chant where community heath carters Regar. Sharghal, in the constant of the def ECG Denice. Alloc Cr 716:4:13 56% 470 ed $\overline{AF-CATCH}$ prepares China Age2 65 yean inclusion: Ecclosion: Anow AF: separes single lead ECG Denice. Alloc Cr 716:4:13 56% 573 $\overline{AF-CATCH}$ prepare China Age2 65 yean inclusion: Ecclosion: Anow AF: separes single lead ECG Denice. Alloc Cr 716:4:13 500 573 55				Senoo et al. 2022 ⁴⁰		Sequence: once per patient, 30 s Biodata: ingle lead ECG Device: Complete, Omron, Kyoto		52%	1607	0.9 (0.5–1.5)
Zapruku ca al. 2020 ⁴ General population based, recruited from 10 pharmacies Region: Squeece: once per patient, 30.8 Bodats: 73.1 \pm 65 65 53 Curbard et al. 2020 ⁴ 6 cties in 3 regione of Poland Age: 265 years inclusion: single lead ECG Device: AlweCor 75.1 \pm 68 3103 Af SNART II Australia Corbard et al. 2020 ⁴ Community based, recruited at GP practices Region: runal sequence: once per patient, 30.8 Bodats: 75.1 \pm 68 3103 Af SNART II Australia Age: 265 years inclusion: -Ecution: minutual PM single lead ECG Device: AlweCor NM 56% 3103 Ordyn et al. 2020 ⁴ Community based, recruited at GP Apordial Community based, recruited at GP Apordial Sequence: once per patient, 30.8 Bodats: NM 56% 737 Ordyn et al. 2020 ⁴ Community based, recruited at GP Apordial Community based, recruited at GP Apordial Sequence: once per patient, 30.8 Bodats: NM 56% 737 75	Systematic, GP-/ Pharmacy-based,	Once, cross-sectional	single lead ECG	Chen et al. 2020 ⁴¹ AF-CATCH, pre-phase		Sequence: once per patient, 30 s Biodata: single lead ECG Device: AliveCor		56%	4370	0.5 (0.3–0.8)
Orchard et al. 2020 ⁴³ Community based, recruited at GP practices Region: unal Equence: once per patient, 30 s Blodata: 751 ± 6.8 53% 3103 AF SMART II Australia Age: 265 years Indusion: Exclusion: implantable PM single lead ECG Device: AllweCor 75.1 ± 6.8 53% 3103 Orwhon et al. 2020 ⁴¹ Community based at 16 Aboriginal Community Health sequence: once per patient, 30 s Blodata: 75.1 ± 6.8 76% 76% Own and/sis of participants aged 265 years Indusion: rural Australia Age: 265 years Indusion: rural Australia Age: 265 years Indusion: Sequence: once per patient, 30 s Blodata: 76.1 ± 7.8 76% 76% 774 Own and/sis of participants aged 265 years Indusion: rural Australia Age: 265 years Indusion: Sequence: once per patient, 30 s Blodata: 76.1 ± 7.8 76% Hong Kong Outpatient AF screening study Nong region Age: 265 years Indusion: Exclusion: dementia, single lead ECG Device: AllweCor 76.4 ± 7.8 774 77 Hong Kong Outpatient AF screening study Kong region Age: 265 years Indusion: Exclusion: dementia, single lead ECG Device: AllweCor 76.4 ± 7.8 76% 76% Hong Kong Outpatient AF screening study Kong region Age: 265 years Indusion: Known AF: screening study Screene patient, 30 s Blodata: 76.4 ± 7.8 76% 76% <td>stationary</td> <td></td> <td></td> <td>Zaprutko et al. 2020⁴²</td> <td></td> <td>Sequence: once per patient, 30 s Biodata: single lead ECG Device: AliveCor</td> <td></td> <td>68%</td> <td>525</td> <td>1.4 (0.6–2.8)</td>	stationary			Zaprutko et al. 2020 ⁴²		Sequence: once per patient, 30 s Biodata: single lead ECG Device: AliveCor		68%	525	1.4 (0.6–2.8)
Gwynn et al. 2020 ⁴ Community backet at 16 Aboriginal Community Health Sequence: once per patient. 30 S Blodata: N/A 56% 146 own and/sis of porticipants aged ≥ 65 years Organizations Region: rural Australia Age: ≥ 45 years Inclusion: single lead ECG Device: AliveCor 146 Sun et al. 2022 ⁴⁵ Organizations Region: rural Australia Age: ≥ 45 years Inclusion: single lead ECG Device: AliveCor 76.4 ± 78 49% 9734 Hong Kong Outpatient AF screening study Kong region Age: ≥ 65 years Inclusion: dementia, single lead ECG Device: AliveCor 76.4 ± 78 49% 9734 Hong Kong Outpatient AF screening study Kong region Age: ≥ 65 years Inclusion: dementia, single lead ECG Device: AliveCor 76.4 ± 78 4339 Verbiest-van Gurp et al. 2022 ⁴⁶ Outpatient Clinics (2 cardiology, 2 IM, 1 geriatric) Region: Hong sequence: once per patient. 30 s Blodata: single 75.4 ± 78 4339 Verbiest-van Gurp et al. 2022 ⁴⁶ Outpatient Clinics (2 cardiology, 2 IM, 1 geriatric) Region: Hong sequence: once per patient Blodata: single 73.5 ± 55 54% 7339 Verbiest-van Gurp et al. 2022 ⁴⁶ Outpatient Clinics (2 cardiology, 2 IM, 1 geriatric) Region: Hong sequence: once per patient Blodata: single 73.5 ± 55 54% 7339 Verbiest-van Gurp et al. 2022 ⁴⁶ Outpatient Clinics (2 cardiology, 2 IM, 1 geriatric) Region: Hong sequence: once per patient Blodata:				Orchard et al. 2020 ⁴³ AF SMART II	Community based, recruited at GP practices Region: rural Australia Age:≥ 65 years Indusion: Exclusion: implantable PM ICD on OAC Known AF excluded	Sequence: once per patient, 30 s Biodata: single lead ECG Device: AliveCor		53%	3103	1.2 (0.8–1.7)
Sun et al. 2024 ⁵ Outpatient clinics (2 cardiology, 2 IN, 1 geriatric) Region: Hong Sequence: once pratient, 30 s Bodata: 76.4±78 47% 7734 Hong Kong Outpatient AF screening study Koon region Age: 265 years Induson: -Exclusion: dementia, single lead ECG Device: AllveCor 76.4±78 47% 7734 Hong Kong Outpatient AF screening study Koon region Age: 265 years Induson: -Exclusion: dementia, single lead ECG Device: AllveCor 76.4±78 79.3 Africation: Screening study Koon region Age: 265 years Induson: -Exclusion: Rowon AF I ead ECG Device: AllveCor 73.5±5.5 54% 4339 Verbiest-van Gurp et al. 2022 ⁴⁶ Outpatient clinics (2 cardiology, 2 IN, 1 geriatric) Region: Hong Requence: once per patient Blodata: single 73.5±5.5 54% 4339 Verbiest-van Gurp et al. 2022 ⁴⁶ Outpatient clinics (2 cardiology, 2 IN, 1 geriatric) Region: Hong Red ECG/BPP plapation Device: 73.5±5.5 54% 7335 Kong region Age: 265 years Inclusion: Known AF I ead ECG/BPP plapation Device: 73.5±5.5 54% 7335			-	Gwynn et al. 2020 ⁴⁴ own analysis of þarticiþants aged≥65 years	Community based at 16 Aboriginal Community Health Organizations Region: rural Australia Âge: 2 45 years Inclusion: Aboriginal heritage Exclusion: -Known AF: separated	Sequence: once per patient, 30 s Biodata: single lead ECG Device: AliveCor		56%	146	0.6 (0.0–3.7)
Verbiest-van Gurp et al. 2022 ⁴⁶ Outpatient clinics (2 cardiology. 2 IM, 1 geriatric) Region: Hong Sequence: once per patient Biodata: single 73.5±5.5 54% 4339 Kong region Age: ≥ 65 years Inclusion: Exclusion: known AF lead ECG/BP/palpation Device: Known AF: separated MyDiagnostick, Microlife BP Monitor, Radial pulse palpation			_	Sun et al. 2022 ⁴⁵ Hong Kong Outpatient AF screening study		Sequence: once per patient, 30 s Biodata: single lead ECG Device: AllveCor		49%	9734	3.0 (2.7–3.4)
			combination	Verblest-van Gurp et al. 2022 ¹⁶	Outpatient clinics (2 cardiology, 2 IM, 1 geriatric) Region: Hong Kong region Age: ≥ 65 years Inclusion: Exclusion: known AF Known AF: separated	Sequence: once per patient Blodata: single lead ECG/BP/palpation Device: VyDlagnostick, Microlifie BP Monitor, Radial pulse palpation		54%	4339	0.8 (0.6–1.1)

Study	Monitoring Technique	Technique	Author, study acronym subgroup/own analysis	Population	Design, intervention	Mean age Female (+/- Std.) (%)	Female (%)	a. 2	Atrial arrhythmia IR (%)
		BP monitor	Jatau et al. 2022 ⁴⁷ What's Your Beat?	General population based, health centers, recruitment via media campaigns Region: Tasmania, Australia Age: ≥ 65 years Inclusion: —Exclusion: severe dementia, known cardiac arrhythmia, imniantable PPVI/ICT Known AF-sochrided	Sequence: once per patient Biodata: BP monitor Device: Microlife	71.0 (68.0– 76.0)	59%	1704	0.9 (0.5–1.5)
	Intermittent	BP monitor	Denas et al. 2020 ⁴⁸	neto, Italy excluded	Sequence: 3 consecutive measurements per visit, unsystematically intermittent at visits over in average 410 days per patient Biodata: RP monitor Dudys Mirrolife	75.5 ± 7.0	58%	14 987	2.5 (2.3–2.8)
		single lead ECG	Zhang et al. 2021 ⁴⁹ AF-CATCH Quarterly-screened subgroup	Community based, community health centers Region: Shanghai Age: ≧ 65 years Inclusion: -Exclusion: -Known AF: excluded	Sequence: intermittent, quarterly Biodata: single lead ECG Device: AliveCor	71.3±6.1	56%	2841	1.4 (1.0–1.9)
			Lubitz et al. 2022 ⁵⁰ VITAL-AF	<	Sequence: intermittent over 12 months at GP visits Biodata: single lead ECG Device: AliveCor	73.9±6.8	60%	15 393	1.7 (1.5–1.9)
		combination	Watanabe et al. 2022 ⁵¹ SCAN-AF	Hospital-affiliated outpatient dinics Region: Japan Age: ≥ 65 years Inclusion: CHA2DS2-V4Sc ≥ 2 or CHADS2 ≥ 1 Exclusion: known AF, use of AAD, inability to use the monitoring devices Known AF: excluded	Sequence: intermittent over 24 weeks Biodata: BP oscillogram, single lead ECG Device: Omron; myBeat	74.0 (69.0– 79.0)	50%	1148	0.8 (0.4–1.5)
Cardiology patients without history of AF	continuous AF	Single lead ECG (ILR)	Svendsen et al. 2021 ⁶ LOOP	Cardiology patients, 4 centers Region: Denmark Age: 70–90 Sequence: continuous, 64.5 months (59.3, years Inclusion: ≥1 of HT, DM. 5T/TIA, HF Exclusion: on OAC, 69.8)*bilodata: single lead ECG (ILR) Device: known CI for OAC, implanted PM/ICD Known AF: excluded Meditronic Reveal LINO ILR	Sequence: continuous, 64.5 months (59.3, 69.8) ^b Biodata: single lead ECG (ILR) Device: Medtronic Reveal LINQ ILR	74.7±4.1	47%	1501	31.8 (29.0–34.8)
			Philippsen et al. 2017 ⁵²		Sequence: continuous, until EN Biodata: PPG (ILR) Device: Medtronic ILR (Reveal XT or Reveal LINQ)	71.3 (67.4, 75.1) ^b	37%	82	207 (12.0-33.2)
The table lists the name parameters are reports Abbreviations: AAD failure; HT, hypertensio	of the study, the popul d for the population a, antiarrhythmic drug(s, n; ICD, implantable car	lation studied, the de: ged ≥ 65 years. Two); BP, blood pressure: dioverter-defibrillatc	sign, age, and sex of the population, the numl studies are included of which only the deals ; 95% Cl, 95% confridence interval; Cl, contra yr; ILR, implantable loop recorder; IM, intern	The table lists the name of the study, the population studied, the design, age, and sex of the population, the number of participants, and the incidence rate of atrial arrhythmias with a 95% confidence interval. When age subgroup data was available or calculable, the study was included and parameters are reported for the population studied are being may be update and sex of the population, the number of participants, and the incidence rate of atrial arrhythmias with a 95% confidence interval. When age subgroup data was available or calculable, the study was included and parameters are reported for the population aged \geq 65 years. Two studies are included of which only the design has been published (Lubitz et al.) or reported on a clinical trials website (AMALFI). Two implantable loop recorder studies are added at the bottom of the table. Abbreviations: AAD, antiarrhythmic drug(s), BP, blood pressure; 95% confidence interval; CI, contraindication; CVD, any cardiovascular disease; DDys, diastolic dysfunction in echocardiography; DM, diabetes mellitus; EF, ejection fraction; GP, general practitioner; HF, heart failure; HT, hypertension; ICD, implantable cardioverter-defibrillator; ILR, implantable loop recorder; IN, internal medicine; IR, incidence rate, IR/10000, incidence rate per 100 000 streemed; n, Population size used for incidence rate calculation; OAS, or al anticoagulation; OSA	a 95% confidence interval. When age subgr website (AMALFI). Two implantable loop i ction in echocardiography: DM, diabetes m 0 000 screened: n. Pobulation size used for	oup data was ava recorder studies ellitus; EF, ejectic	ailable or calcula s are added at t on fraction; GP, calculation; OA	ble, the sti he botton general p C, oral an	ldy was included and n of the table. actitioner; HF, heart ticoagulation; OSAS,

obstructive sleep apnea syndrome; PAD, peripheral artery disease; PM, pacemaker; poAF, postoperative AF, ST/TA, stroke or TA; VD, vascular disease (in CHA2DS2-VASc).

³This study included participants without knowledge of the history of atrial fibrillation but was included in the review due to its sample size and population-wide approach. Reported is the incidence rate of screen-positive participants (irregular pulse notification). Of these, 34% were

 $^{\mathrm{b}}\mathsf{M}\mathsf{edian}$ age and interquartile range (IQR) are reported. diagnosed on a subsequent Holter ECG.

^cProportion of females not available for reported age group.




Figure 2 Detection of atrial arrhythmias over time in the study population. The bold continuous black line shows the Kaplan-Meier estimated cumulative event rate with corresponding 95% confidence interval (dotted black lines). The dotted green vertical line identifies the time point of the primary outcome, detection of atrial arrhythmias within 28 days of screening. Screening beyond this time point identified only a few additional cases.

Adverse events

SMART in OAC—AFNET 9 is a low-risk study using approved procedures to screen for atrial arrhythmias. Adverse events of interest related to the study procedures (e.g. unwanted effects of the wearable, in this case, a wristband) were noted by study centres if voiced by participants and collected in a questionnaire for participants following an invitation to a Holter ECG.

Statistical analyses

All analyses were prespecified in a dedicated statistical analysis plan signed on 31 January 2022 before accessing the data. The primary analysis was based on the full analysis data set (FAS), consisting of all participants that consented to screening and provided at least one data point. A sensitivity analysis was performed in a per protocol population including all participants that used the wearable as intended, i.e. used the device until screening rendered a positive result or in whom an analysable PPG signal was available for at least 300 h in the first 4 weeks of monitoring. Demographics and baseline characteristics are summarized using descriptive statistics. The detection rate of AA was calculated together with the corresponding two-sided 95% Clopper-Pearson Cl. If participants discontinued participation, the information gathered until discontinuation was analysed. Time to first AA detection was analysed by taking death as a competing risk into account using Aalen-Johansen curves. A multivariable logistic model utilizing Firth's bias-reduced penalized-likelihood was used to simultaneously identify predictors of AA. All analyses were carried out using R v4.0.5 (R Core Team, Vienna).

Role of the funding source

Smart in OAC—AFNET 9 is an investigator-initiated trial designed and executed by the authors. AFNET oversaw the trial as the legal sponsor, with U.S. serving as sponsor representative on the steering committee. Daiichi-Sankyo Europe provided funding for the study to AFNET and held a non-voting seat on the steering committee. Preventicus provided access to their PPG-based AF screening technology and Telecare Health system.


Data sharing

The protocol, informed consent in its written form, and statistical analysis plan are available in this paper. Study data will be made available for research purposes for at least 5 years after the completion of the study. Please direct inquiries including an outline of the planned analyses to info@kompetenznetz-vorhofflimmern.de; info@af-net.eu. Data will be made available by AFNET on reasonable request.

Results

Participants

A total of 882 participants were PPG-screened in Germany, Poland, and Spain between 01 February 2021 and 31 January 2022 (*Figure 1*). In Spain, the Barcelona ethics committee required an in-person consent process with a hand-signed consent form. Five hundred (57%) participants were female, 414 (47%) participants reported known hypertension, and 97 (11%) reported known diabetes (*Table 1*).



Downloaded from https://academic.oup.com/ehjdh/article/3/4/610/6783214 by guest on 20 December 2023

Figure 3 Distribution of wearable screening duration (hours transmitted on x-axis, hours usable on y-axis) PPG screening analysis stopped after AA was detected and confirmed by the analysis service.

The age ranged from 65 to 90 years (mean age 71 ± 5 years). The majority of participants (72%) were reached by media campaigns in newspapers and television or by word of mouth and town hall meetings for senior citizens (category 'other' in Supplementary material online, *Figure* S2). The remaining participants were attracted by leaflets (11%), identified by general practitioners made aware of the study (9%), a website (4%), the site team hospital ambulatory settings (2%), or pharmacies (2%). Communication about the study in targeting audiences of older adults, including newspaper and television adverts, video messages, and town hall meetings, were associated with high recruitment rates (see Supplementary material online, *Figure* S2).

Primary outcome

Atrial arrhythmias were detected in 44/882 participants [5.0%, 95% CI (3.6–6.6)] within 28 days of monitoring (*Figure 2*). Arrhythmia

detection rate was higher in the 1st week of monitoring compared with subsequent weeks: The atrial arrhythmia incidence rate was 3.4 participants with atrial arrhythmias/100 monitored weeks (95% Cl 2.4–4.9) in the 1st week of monitoring and between 0.12 and 0.71 in subsequent weeks [average incidence rate for week 2–4 was 0.55 (0.33–0.93), P < 0.001 for incidence rate in the 1st week vs. weeks 2–4, *Figure 2*].

Secondary outcomes

Atrial arrhythmias were detected in 53/882 participants (6%) within 8 weeks of monitoring (*Figure 2*). The time from initiation of monitoring to detection of atrial arrhythmias was relatively short, confirming the higher detection rate early during monitoring (*Figure 2*).

A prespecified sensitivity analysis confined to participants who used the device per protocol within the first 4 weeks of monitoring, found a similar detection rate of 44/805 5.5% (95% Cl 4.0–7.3).




Figure 4 Forest plot of factors associated with AA. Older age was the only factor associated with atrial arrhythmias in this study.

Participants with atrial arrhythmias were older than those without atrial arrhythmias (*Table 1* and *Figure 4*). There were no differences in the detection of atrial arrhythmias by region, by route of invitation to the study, or by sex (*Table 1* and *Figure 4*). Quality of life was similar in participants with atrial arrhythmias (*Table 1*). Older age was the only parameter associated with atrial arrhythmia detection in this study (*Figure 4*).

Participants transmitted a mean of 530 h of PPG recordings over the first 696 h of monitoring (76% of the maximal monitoring duration within 4 weeks plus the inclusion day. Of these, 240 h (45%) were of sufficient quality for rhythm analyses (*Figure 3*). The transmission rate dropped slightly to 400 h/28 days in weeks 5–8 of monitoring.

Time of day of AA detection was evaluated in participants with any AA detection (53/882, 6%): There were no differences between the number of transmitted PPG-minutes observed between daytime (6:00 am to 10:00 pm) and nighttime. While 73% of recorded PPG-minutes during nighttime could be used for AA detection, only 26% of recorded PPG-minutes during daytime were analysable (P < 0.0001). In participants with any AA detection, AA burden at night was 1.57-fold higher than during the daytime, with daytime AA burden of 9 min/h and nighttime AA burden of 14 min/h of analysable recording [(95% Cl 1.15–2.14), P = 0.004]. Just over half of the

participants (53%) participated without any in-person contact, while 47% of participants received personal assistance with the device. At the Barcelona site, the 30 participants were required to sign a written informed consent. Technical problems with Bluetooth coupling and recoupling, omission of recharging the smartphone, or local skin irritation during the summer heat, were reasons for queries to technical support and study sites and discontinuation of monitoring. In addition to communication routes via the app, SMS, email, and staff at the study sites, a central technical telephone support hotline was provided. About half of the participants (51%) contacted the central telephone hotline for queries. Most of the queries regarded pairing and coupling for data transfer.

All 53 participants with PPG-detected atrial arrhythmias were invited to undergo a 14-day event recorder ECG. Of these, 45 later underwent a 14-day event recorder ECG as part of the study. Eight participants did not have that test as part of the study, as they either had symptoms and were diagnosed with AF in the hospital or aimed to receive further diagnostics elsewhere with results not known. An additional random control sample without PPG-detected atrial arrhythmias underwent the same event monitoring. Event monitoring started with a median delay of 31 days (IQR 21, 48) after AA detection in PPG. Event-recorder Holter ECGs identified AF in 27/45 participants with previously PPG-detected arrhythmias, and none (0/7) participants without PPG-detected arrhythmias. Participants undergoing the study Holter ECG filled in a second questionnaire depicted in Supplementary material online, *Table* S2. The estimated CHA₂DS₂-VASc-Score was 2.6 ± 1.4 , sufficient to decide on oral anticoagulation.

Discussion

Main findings. **Smart**phone and wearable detected atrial arrhythmia **in O**lder **A**dults **C**ase finding study (Smart in OAC—AFNET 9) successfully deployed a fully digital, consumer-electronics based system to detect atrial arrhythmias in older adults in several European countries. The main results are:

- A fully digital wearable system worn for 4 weeks identifies atrial arrhythmias in 5% of older adults (> 65 years of age).
- (2) The majority of participants were identified using targeted public media communications or direct contacts. Offers of remote technical assistance were accepted and compliance was high, showing feasibility and scalability for this age group if targeted.
- (3) Detection rates for atrial arrhythmias are high in the 1st week of PPG monitoring, and taper off thereafter, suggesting that relatively short monitoring periods may be sufficient to detect older adults with atrial arrhythmias.

These findings encourage the use of fully digital, consumerelectronics based PPG systems to screen for atrial arrhythmias in older adults.

Atrial arrhythmia detection in Smart in OAC—AFNET 9. We systematically reviewed the performance of electronic devices to screen for atrial arrhythmias in older adults 65 years of age and above. Five systematic reviews of arrhythmia detection via mobile health applications published between 2020 and 2022²⁵⁻²⁸ yielded 28 potentially eligible studies. A MEDLINE search conducted on 25 February 2022 (search terms see Supplementary material online) revealed 235 unique records published between 2020 and 2022, containing 23 already found eligible via the initial five systematic reviews. During revision, the MEDLINE search was repeated and yielded additional 70 potentially eligible articles. Overall, 71 full texts were assessed which yielded 26 included studies (Table 2, Supplementary material online, Figure S1). In cases where age subgroup data were reported in a trial, it was still included and the incidence rate was calculated from the reported patient numbers.^{15,16} The same was performed when the original study only reported comparative outcomes such as hazard ratio but counts of diagnosed patients and totally screened patients were also reported.³⁷

Published studies in populations and cohorts including a subgroup with a comparable age range and mostly comparable screening technologies reported atrial arrhythmia detection rates between 2.8 and 3.1%, ^{15,16} less than the smartphone and wearable PPG-based incidence rate in Smart in OAC—AFNET 9 of 5% in 4 weeks. When screened populations were enriched using clinical risk factors or elevated NT-proBNP concentrations,³¹ incidence rates increased (2.7–4.4%, ^{29,31,33}) Published reports suggest that continuous PPG monitoring is associated with higher (2.5 -5.3%, ^{30,32,34}) arrhythmia detection rates than intermittent monitoring (0.9–3.8%, ^{35–38}) confirmed in this study. The rate of ECG-confirmed AF in the Smart in OAC substudy via Holter or the clinical setting was of 3.1–3.4% of

the overall study population, within the range we had estimated in this age group, but lower than previous PPG-detected arrhythmias in the same study, pointing to the paroxysmal character of AF. However, the confirmation rate of 60% (27 AF-positive out of 45 AA-positively screened participants) is higher than in the younger population of the Apple Heart Study.¹⁵ This has several potential explanations. One reason could be that Smart in OAC only screened for arrhythmia episodes lasting 6 min or longer, while Apple Heart accepted shorter arrhythmia durations. Three remotely conducted, large and population- and consumer-technology based landmark trials in AF screening via continuous PPG monitoring are the Apple Heart Study.¹⁵ the Pre-MAFA II trial (Huawei Heart Study)¹⁶ and the Fitbit Heart Study.²⁰ The AA screen positive rates were 0.52%, 0.23%, and 1.0% in the overall screened population and 3.1, 2.8, and 3.6% in those aged 65 years and older.

Much higher detection rates were observed when opportunistic screening was performed or when data from implantable loop recorders were used to screen pre-selected, multimorbid patient populations.^{6,52} Subclinical AF episodes lasting longer than 6 min were detected in 26% of patients in a study of continuous single lead ECG monitoring.³⁴ Studies employing implantable loop recorders also employed the cut-off of 6 min⁶ and a recent meta-analysis suggests that stroke risk is very low in patients with episodes shorter than 6 min.⁹

The AA detection yield in *Smart in OAC—AFNET 9* was slightly higher than in similar published screening trials in a comparable population only preselected by age above 65 years. Reasons for high AA yield could include the near continuous monitoring with a wearable PPG-sensor, and high compliance with wearing the device during night-time. In participants in which AA was detected, the yield was nearly 1.6-fold elevated during nighttime (10 p.m to 6 a.m) compared with daytime even after correcting for better signal quality at night. In line with this observation, Deguchi et al.⁵³ reported an elevated probability of AF onset around midnight from Holter-monitoring data of 217 patients with paroxysmal AF.

In 83% of participants, AA was detected within the first 28 days of monitoring and in most participants AA was detected within the first 14 days.

The minimal duration for arrhythmia detection used in Smart in OAC—AFNET 9 was 6 min.²¹ This is longer than the ESC guidelines definition of AF when detected on a clinical ECG, and longer than the minimal arrhythmia duration suggested for AF screening using consumer electronics in a recent EHRA guide.⁷ Rare arrhythmias of 6 min duration or more, detected within three months of screening using an implanted device, are associated with an increased risk of stroke.^{10,22} Six minutes of atrial arrhythmias are also sufficiently long to allow good differentiation of atrial arrhythmias from artefacts or other rhythm irregularities in wearables.¹⁹ These considerations informed our decision to screen for atrial arrhythmias of 6 min duration or more. The authors expect that there will be a gradual increase in the risk of ischaemic events that are preventable by oral anticoagulation as the arrhythmia duration, and by inference the arrhythmia burden, increases,¹⁰ a concept that was also presented in the most recent AFNET/EHRA consensus statement.¹²

It is therefore worth considering that screening pathways should address large cohorts or populations with rather short (14–28 days) but continuous monitoring periods, emphasizing night time monitoring, rather than unselective screening of smaller populations over a long time. Digital recruitment and consenting processes as demonstrated in *Smart in OAC—AFNET 9* can help include large populations even during a pandemic. The recently published eBRAVE-AF screening trial invited 67.488 German private healthcare policyholders aged 50 years and over of whom 5551 (8.2%) with a median age of 65 years were digitally enrolled.⁵⁴ The study compared the use of a smartphone camera PPG-based intermittent screening application to usual care in a cross-over design and could show increased yields of newly diagnosed AF; additionally, the median age was older than the digitally enrolling Apple or Huawei Heart studies. *Smart in OAC—AFNET 9* targeted and enrolled an even older population following and openly advertised invitations independent of their insurer.

Apart from age, pre-selection of participants did not contribute to the increased screening yield in *Smart in OAC*—*AFNET 9*. Both age and self-reported estimated CHA₂DS₂-VASc-Score were comparable to or even lower than in similar studies^{29–31,33,34} and most participants were recruited via targeted public media communications and not from hospital patient pools. The ability of night-time recordings may however have increased the yield.

Limitations. While the communication around the study and the options for participation were designed to enable inclusive participation, we cannot exclude some selection of participants that may have influenced the observed atrial arrhythmia detection rate, based on access to a personal smartphone and wireless internet access. Our study targeted the older European population, and the participants were therefore mostly white. Observations may differ in other ethnicities. The remote study design relied on self-reporting of pre-existing medical conditions like known AF, hypertension, or diabetes as well as demographic data by participants. This may have contributed to comparably low reported rates of concomitant medical conditions in this population and also in the screen-positive AA group. Self-reported numbers in this study for hypertension and diabetes were similar to those observed in STROKESTOP.⁵

The design of our study included subsequent Holter ECG event recorder assessment in participants with positive PPG AA to ensure that participants would be reassured or receive a diagnosis of AF and subsequent treatment as required. Due to the transient nature of paroxysmal atrial arrhythmias and the lack of a simultaneous PPG signal analysis together with the ECG (as the PPG analysis stopped after a positive screen), the assessment in this study does not provide valid information on diagnostic accuracy. We still report results of Holter ECGs as these can be expected in clinical practice if PPG is used for screening. Performing Holter-ECGs on negatively screened participants was limited by operational difficulties as some participants without relevant findings were less keen to undergo further tests and staff of centres were less motivated to provide access to the Holter-ECGs to negatively screened participants during COVID-19 waves. In the future, this could be partially overcome by a central distribution system.

Adverse events directly associated with the PPG recording were minor skin reactions to the wristband and were only reported during the summer months (see Supplementary material online, *Table S1*). A changeable cotton wristband was offered to replace the standard silicone wristband and participants were able to use any personal wristband of their choice if it could be attached to the PPG unit. Data on the cost effectiveness of the tested screening system have been published.^{55,56} The results of Smart in OAC—AFNET 9 will be an important component of a planned health economic (HE) analysis which is beyond the scope of this report.

Conclusions

A fully digital, wearable based PPG screening identifies atrial arrhythmias in 5% of an openly invited population of older adults of 65 years or above without previously known AF or anticoagulation therapy. Advertising targeting older populations and remote technical support when needed enable broad participation and adequate monitoring durations. The majority of atrial arrhythmias were detected a few weeks after the initiation of screening.

SMART in OAC—AFNET 9 results provide robust information on the prevalence of PPG-detected atrial arrhythmias in older adults. The study provides data on different methods to reach out to such populations to offer arrhythmia screening and on patient characteristics with PPG-detected arrhythmias. The study thus generates robust information for the planning of an outcome trial.

Author contributions

A.Z., E.G., L.F., R.B.S., T.H., P.K., and U.S. planned the study. R.B.S., P.K., L.F., A.Z.-H., D.H., E.C., D.C., and K.J. designed the protocol. K.J., E.C., A.Z.-H., L.F., R.B.S., D.C., and E.G. designed lay-friendly information and prepared ethics applications. R.B.S., S.J.W., A.Z.-H., D.D., and E.G. contributed to participant recruitment and further diagnostics via study centres. A.Z. and E.V. were responsible for statistical analysis. J.O., K.J., and L.F. prepared the literature meta-analysis. E.V., J.O., and L.F. prepared result figures and tables. L.F., P.K., and E.V. wrote the manuscript. All authors made critical comments on the manuscript. L.F., E.V., J.O., P.K., and K.J. revised the study in response to reviewer comments.

Lead author biography



Prof Dr Larissa Fabritz studied medicine in Heidelberg, Münster, Lille, Concepcion, and Zurich, including a research year in Washington, DC, USA. Larissa trained at University Hospital Münster, Germany, with habilitation (D.S.) and specialist registration. In 2011, Larissa accepted a tenured clinical academic position at the University of Birmingham, UK, and was promoted to Chair in

Cardiovascular Sciences there. She holds a Chair in Inherited Cardiac Conditions at the Center of Cardiovascular Sciences, UKE Hamburg, Germany. Larissa published on arrhythmias and cardiomyopathies. As a member of ESC working groups, EHRA, DZHK, and AFNET steering committee, she contributes to European research consortia and ESC guidelines.

Supplementary material

Supplementary material is available at European Heart Journal – Digital Health online.

Acknowledgements

We thank study participants, all colleagues at study sites and at AFNET for their contribution to the study, especially Anke Heiermann and Simone Neumann.

Funding

The design of this investigator-initiated trial was developed by the authors and AFNET. Sponsor of the trial is AFNET (https://www. kompetenznetz-vorhofflimmern.de). Financial support was provided from Daiichi Sankyo Europe to AFNET. Preventicus provided the cloud based analytic service Preventicus Heartbeats for analysing the PPG data and screen for AA; plus the comprehensive IT backbone. L.F., P.K., E.G., and U.S. received funding from EU Horizon 2020 CATCH ME (grant agreement number 633196), and MAESTRIA (grant agreement number 965286). L.F. and P.K. have received funding from Accelerator Award by the British Heart Foundation AA/18/2/34218. L.F. is further part-funded by National Institute for Health and Care Research (NIHR) award 1002898 (APRAISE-AS) at University of Birmingham, AFFECT-EU grant agreement number 847770 and German Center for Cardiovascular Research (DZHK). U.S. received funding from the Dutch Heart Foundation (CVON2014-09, RACE V Reappraisal of Atrial Fibrillation: Interaction between hyperCoagulability, Electrical remodeling, and Vascular Destabilisation in the Progression of AF). R.B.S. has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement number 648131), from the European Union's Horizon 2020 research and innovation programme [grant agreement number 847770 (AFFECT-EU)] and German Center for Cardiovascular Research (DZHK e.V.) (81Z1710103), German Ministry of Research and Education (BMBF 01ZX1408A) and ERACoSysMed3 (031L0239). P.K. was partially supported by European Union BigData@Heart (grant agreement EU IMI 116074), AFFECT-AF (grant agreement number 847770), British Heart Foundation (PG/17/30/32961; PG/20/22/35093), German Centre for Cardiovascular Research supported by the German Ministry of Education and Research (DZHK), and Leducq Foundation. K.J. is partfunded by the National Institute for Health and Care Research (NIHR) Applied Research Collaboration (ARC) West Midlands and Medical Research Council. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

Conflict of interest: L.F. has received institutional research grants and non-financial support from European Union, British Heart Foundation, Medical Research Council (UK), NIHR, German Centre for Cardiovascular Research (DZHK), several biomedical companies and previously DFG. The Institute of Cardiovascular Research, University of Birmingham, has received an Accelerator Award by the British Heart Foundation AA/18/2/34218. L.F. and P.K. are listed as inventor of two patents held by University of Birmingham (Atrial Fibrillation Therapy WO 2015140571, Markers

for Atrial Fibrillation WO 2016012783). U.S. received consultancy fees or honoraria from Università della Svizzera Italiana (USI, Switzerland), Roche Diagnostics (Switzerland), EP Solutions Inc. (Switzerland), Johnson & Johnson Medical Limited, (UK). U.S. is cofounder and shareholder of YourRhythmics BV, a spin-off company of the University Maastricht. R.B.S. has received speaker fees from BMS/Pfizer. P.K. receives research support for basic, translational, and clinical research projects from European Union, British Heart Foundation, Leducg Foundation, Medical Research Council (UK), and German Centre for Cardiovascular Research (DZHK), from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies in the past, but not in the last three years. K.J. is the trial Steering Committee chair and member of several committees of NIHR funded studies (no honorarium) and sub-committee chair of the NIHR Programme Grants for Applied Health Research. T.H. is the founder and CEO of Preventicus. E.C. and D.H. received funding from Daiichi Sankyo Europe and study devices from Preventicus GmbH. D.C. has received consulting fees from Bayer, Boehringer Ingelheim, Daiichi Sankyo and Pfizer. JO received support for attending meetings and/ or travel from the EHRA 2022 Educational Grand and financial support for abroad studies and research from the German Academic Scholarship Foundation. E.V. and A.Z. received institutional grants from AFNET and from Biotronik.

Data availability

Data will be made available by AFNET on reasonable request.

References

- US Preventive Services Task Force, Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, Davis EM, Donahue KE, Doubeni CA, Epling JW Jr, Kubik M, Li L, Ogedegbe G, Pbert L, Silverstein M, Stevermer J, Tseng CW, Wong JB. Screening for atrial fibrillation: US preventive services task force recommendation statement. JAMA 2022;**327**:360–367.
- Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, Fetsch T, van Gelder IC, Haase D, Haegeli LM, Hamann F, Heidbuchel H, Hindricks G, Kautzner J, Kuck KH, Mont L, Ng GA, Rekosz J, Schoen N, Schotten U, Suling A, Taggeselle J, Themistoclakis S, Vettorazzi E, Vardas P, Wegscheider K, Willems S, Crijns H, Breithardt G, EAST-AFNET 4 Trial Investigators. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med 2020;383:1305–316.
- Grond M, Jauss M, Hamann G, Stark E, Veltkamp R, Nabavi D, Horn M, Weimar C, Kohrmann M, Wachter R, Rosin L, Kirchhof P. Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. Stroke 2013;44:3357–3364.
- 4. Haeusler KG, Kirchhof P, Kunze C, Tutuncu S, Fiessler C, Malsch C, Olma MC, Jawad-Ul-Qamar M, Kramer M, Wachter R, Michalski D, Kraft A, Rizos T, Groschel K, Thomalla G, Nabavi DG, Rother J, Laufs U, Veltkamp R, Heuschmann PU, Endres M, Mon DI. Systematic monitoring for detection of atrial fibrillation in patients with acute ischaemic stroke (MonDAFIS): a randomised, open-label, multi-centre study. *Lancet Neurol* 2021;**20**:426–436.
- Svennberg E, Friberg L, Frykman V, Al-Khalili F, Engdahl J, Rosenqvist M. Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial. *Lancet* 2021;**398**:1498–1506.
- Svendsen JH, Diederichsen SZ, Hojberg S, Krieger DW, Graff C, Kronborg C, Olesen MS, Nielsen JB, Holst AG, Brandes A, Haugan KJ, Kober L. Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial. *Lancet* 2021;**398**:1507–1516.
- 7. Svennberg E, Tjong F, Goette A, Akoum N, Di Biase L, Bordachar P, Boriani G, Burri H, Conte G, Deharo JC, Deneke T, Drossart I, Duncker D, Han JK, Heidbuchel H, Jais P, de Oliviera Figueiredo MJ, Linz D, Lip GYH, Malaczynska-Rajpold K, Marquez M, Ploem C, Soejima K, Stiles MK, Wierda E, Vernooy K, Leclercq C, Meyer C, Pisani C, Pak HN, Gupta D, Purerfellner H, Crijns H, Chavez EA, Willems S, Waldmann V, Dekker L, Wan E, Kavoor P, Turagam MK, Sinner M. How to use digital devices to detect and manage arrhythmias: an EHRA practical guide. *Europace* 2022;**24**: 979–1005.

- Healey JS, Alings M, Ha A, Leong-Sit P, Birnie DH, de Graaf JJ, Freericks M, Verma A, Wang J, Leong D, Dokainish H, Philippon F, Barake W, McIntyre WF, Simek K, Hill MD, Mehta SR, Carlson M, Smeele F, Pandey AS, Connolly SJ, ASSERT-II Investigator. Subclinical atrial fibrillation in older patients. *Circulation* 2017;**136**:1276–1283.
- Mahajan R, Perera T, Elliott AD, Twomey DJ, Kumar S, Munwar DA, Khokhar KB, Thiyagarajah A, Middeldorp ME, Nalliah CJ, Hendriks JML, Kalman JM, Lau DH, Sanders P. Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis. *Eur Heart J* 2018;**39**:1407–1415.
- Bertaglia E, Blank B, Blomstrom-Lundqvist C, Brandes A, Cabanelas N, Dan GA, Dichtl W, Goette A, de Groot JR, Lubinski A, Marijon E, Merkely B, Mont L, Piorkowski C, Sarkozy A, Sulke N, Vardas P, Velchev V, Wichterle D, Kirchhof P. Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence. *Europace* 2019;21:1459–1467.
- Van Gelder IC, Healey JS, Crijns HJ, Wang J, Hohnloser SH, Gold MR, Capucci A, Lau CP, Morillo CA, Hobbelt AH, Rienstra M, Connolly SJ. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. *Eur Heart J* 2017;**38**: 1339–1344.
- 12. Schnabel RB, Marinelli EA, Arbelo E, Boriani G, Boveda S, Buckley CM, Camm AJ, Casadei B, Chua W, Dagres N, de Melis M, Desteghe L, Diederichsen SZ, Duncker D, Eckardt L, Eisert C, Engler D, Fabritz L, Freedman B, Gillet L, Goette A, Guasch E, Svendsen JH, Hatem SN, Haeusler KG, Healey JS, Heidbuchel H, Hindricks G, Hobbs FDR, Hubner T, Kotecha D, Krekler M, Leclercq C, Lewalter T, Lin H, Linz D, Lip GYH, Lochen ML, Lucassen W, Malaczynska-Rajpold K, Massberg S, Merino JL, Meyer R, Mont L, Myers MC, Neubeck L, Niiranen T, Oeff M, Oldgren J, Potpara TS, Psaroudakis G, Purerfellner H, Ravens U, Rienstra M, Rivard L, Scherr D, Schotten U, Shah D, Sinner MF, Smolnik R, Steinbeck G, Steven D, Svennberg E, Thomas D, True Hills M, van Gelder IC, Vardar B, Pala E, Wakili R, Wegscheider K, Wieloch M, Willems S, Witt H, Ziegler A, Daniel Zink M, Kirchhof P. Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference. *Europace* 2022:euac062. doi:10.1093/europace/euac062.
- Lopes RD, Alings M, Connolly SJ, Beresh H, Granger CB, Mazuecos JB, Boriani G, Nielsen JC, Conen D, Hohnloser SH, Mairesse GH, Mabo P, Camm AJ, Healey JS. Rationale and design of the Apixaban for the reduction of thrombo-embolism in patients with device-detected sub-clinical atrial fibrillation (ARTESiA) trial. Am Heart J 2017;**189**:137–145.
- 14. Kirchhof P, Blank BF, Calvert M, Camm AJ, Chlouverakis G, Diener HC, Goette A, Huening A, Lip GYH, Simantirakis E, Vardas P. Probing oral anticoagulation in patients with atrial high rate episodes: rationale and design of the non-vitamin K antagonist oral anticoagulants in patients with atrial high rate episodes (NOAH-AFNET 6) trial. Am Heart J 2017;**190**:12–18.
- Perez MV, Mahaffey KW, Hedlin H, Rumsfeld JS, Garcia A, Ferris T, Balasubramanian V, Russo AM, Rajmane A, Cheung L, Hung G, Lee J, Kowey P, Talati N, Nag D, Gummidipundi SE, Beatty A, Hills MT, Desai S, Granger CB, Desai M, Turakhia MP. Apple heart study I. Large-scale assessment of a smartwatch to identify atrial fibrillation. N Engl J Med 2019;**381**:1909–1917.
- Guo Y, Wang H, Zhang H, Liu T, Liang Z, Xia Y, Yan L, Xing Y, Shi H, Li S, Liu Y, Liu F, Feng M, Chen Y, Lip GYH, MAFA II Investigators. Mobile photoplethysmographic technology to detect atrial fibrillation. J Am Coll Cardiol 2019;74:2365–2375.
- 17. Freedman B, Camm J, Calkins H, Healey JS, Rosenqvist M, Wang J, Albert CM, Anderson CS, Antoniou S, Benjamin EJ, Boriani G, Brachmann J, Brandes A, Chao TF, Conen D, Engdahl J, Fauchier L, Fitzmaurice DA, Friberg L, Gersh BJ, Gladstone DJ, Glotzer TV, Gwynne K, Hankey GJ, Harbison J, Hillis GS, Hills MT, Kamel H, Kirchhof P, Kowey PR, Krieger D, Lee VWY, Levin LA, Lip GYH, Lobban T, Lowres N, Mairesse GH, Martinez C, Neubeck L, Orchard J, Piccini J, Poppe K, Potpara TS, Puererfellner H, Rienstra M, Sandhu RK, Schnabel RB, Siu CW, Steinhubl S, Svendsen JH, Svennberg E, Themistoclakis S, Tieleman RG, Turakhia MP, Tveit A, Uittenbogaart SB, Van Gelder IC, Verma A, Wachter R, Yan BP, AF-Screen Collaborators. Screening for atrial fibrillation: A report of the AF-SCREEN international collaboration. *Circulation* 2017;**135**:1851–1867.
- Koenig N, Seeck A, Eckstein J, Mainka A, Huebner T, Voss A, Weber S. Validation of a new heart rate measurement algorithm for fingertip recording of video signals with smartphones. *Telemed J E Health* 2016;22:631–636.
- Dorr M, Nohturfft V, Brasier N, Bosshard E, Djurdjevic A, Gross S, Raichle CJ, Rhinisperger M, Stockli R, Eckstein J. The WATCH AF trial: SmartWATCHes for detection of atrial fibrillation. JACC Clin Electrophysiol 2019;5:199–208.
- 20. Lubitz SA, Faranesh AZ, Atlas SJ, McManus DD, Singer DE, Pagoto S, Pantelopoulos A, Foulkes AS. Rationale and design of a large population study to validate software for the assessment of atrial fibrillation from data acquired by a consumer tracker or smartwatch: the fitbit heart study. Am Heart J 2021;238:16–26.
- Fabritz L, Connolly D, Czarnecki E, Dudek D, Zlahodaa-Huzior A, Guasch E, Haase D, Huebner T, Jolly K, Kirchhof P, Schotten U, Zapf A, Schnabel RB. Remote design of a smartphone and wearable detected atrial arrhythmia in older adults case finding study: smart in OAC—AFNET 9. *Front Cardiovasc Med* 2022:**9**:839202.

- Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES, Hohnloser SH. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012;366:120–129.
- Reiffel JA, Verma A, Kowey PR, Halperin JL, Gersh BJ, Wachter R, Pouliot E, Ziegler PD, Investigators RA. Incidence of previously undiagnosed atrial fibrillation using insertable cardiac monitors in a high-risk population: the REVEAL AF study. JAMA Cardiol 2017;2:1120–1127.
- 24. Kirchhof P, Bax J, Blomstrom-Lundquist C, Calkins H, Camm AJ, Cappato R, Cosio F, Crijns H, Diener HC, Goette A, Israel CW, Kuck KH, Lip GY, Nattel S, Page RL, Ravens U, Schotten U, Steinbeck G, Vardas P, Waldo A, Wegscheider K, Willems S, Breithardt G. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'. Eur Heart J 2009;**30**:2969–2977c.
- Perales CRL, Van Spall HGC, Maeda S, Jimenez A, Latcu DG, Milman A, Kirakoya-Samadoulougou F, Mamas MA, Muser D, Casado Arroyo R. Mobile health applications for the detection of atrial fibrillation: a systematic review. *Europace* 2021; 23:11–28.
- 26. Varma N, Cygankiewicz I, Turakhia M, Heidbuchel H, Hu Y, Chen LY, Couderc JP, Cronin EM, Estep JD, Grieten L, Lane DA, Mehra R, Page A, Passman R, Piccini J, Piotrowicz E, Piotrowicz R, Platonov PG, Ribeiro AL, Rich RE, Russo AM, Slotwiner D, Steinberg JS, Svennberg E. 2021 ISHNE/HRS/EHRA/APHRS collaborative statement on mHealth in arrhythmia management: digital medical tools for heart rhythm professionals: from the international society for Holter and noninvasive electrocardiology/heart rhythm society/European heart rhythm association/Asia pacific heart rhythm society. J Arrhythm 2021;**37**:271–319.
- Ding EY, Marcus GM, McManus DD. Emerging technologies for identifying atrial fibrillation. *Circ Res* 2020;**127**:128–142.
- Kahwati LC, Asher GN, Kadro ZO, Keen S, Ali R, Coker-Schwimmer E, Jonas DE. Screening for atrial fibrillation: updated evidence report and systematic review for the US preventive services task force. JAMA 2022;327:368–383.
- Langer A, Healey JS, Quinn FR, Honos G, Nault I, Tan M, Camara D, Newman DM, Godin R, Program AA. Detection of atrial fibrillation in asymptomatic at-risk individuals. Int J Cardiol 2021;334:55–57.
- Gladstone DJ, Wachter R, Schmalstieg-Bahr K, Quinn FR, Hummers E, Ivers N, Marsden T, Thornton A, Djuric A, Suerbaum J, von Grunhagen D, McIntyre WF, Benz AP, Wong JA, Merali F, Henein S, Nichol C, Connolly SJ, Healey JS, Investigators SA, Coordinators. Screening for atrial fibrillation in the older population: a randomized clinical trial. *JAMA Cardiol* 2021;6:558–567.
- Gudmundsdottir KK, Fredriksson T, Svennberg E, Al-Khalili F, Friberg L, Frykman V, Hijazi Z, Rosenqvist M, Engdahl J. Stepwise mass screening for atrial fibrillation using N-terminal B-type natriuretic peptide: the STROKESTOP II study. *Europace* 2020; 22:24–32.
- Rooney MR, Soliman EZ, Lutsey PL, Norby FL, Loehr LR, Mosley TH, Zhang M, Gottesman RF, Coresh J, Folsom AR, Alonso A, Chen LY. Prevalence and characteristics of subclinical atrial fibrillation in a community-dwelling elderly population: the ARIC study. *Circ Arrhythm Electrophysiol* 2019;**12**:e007390.
- 33. Steinhubl SR, Waalen J, Edwards AM, Ariniello LM, Mehta RR, Ebner GS, Carter C, Baca-Motes K, Felicione E, Sarich T, Topol EJ. Effect of a home-based wearable continuous ECG monitoring patch on detection of undiagnosed atrial fibrillation: the mSToPS randomized clinical trial. JAMA 2018;**320**:146–155.
- Heckbert SR, Austin TR, Jensen PN, Floyd JS, Psaty BM, Soliman EZ, Kronmal RA. Yield and consistency of arrhythmia detection with patch electrocardiographic monitoring: the multi-ethnic study of atherosclerosis. J Electrocardiol 2018;51:997–1002.
- 35. Berge T, Brynildsen J, Larssen HKN, Onarheim S, Jenssen GR, Ihle-Hansen H, Christophersen IE, Myrstad M, Rosjo H, Smith P, Tveit A. Systematic screening for atrial fibrillation in a 65-year-old population with risk factors for stroke: data from the Akershus Cardiac Examination 1950 study. *Europace* 2018;20:f299–f305.
- Ghazal F, Theobald H, Rosenqvist M, Al-Khalili F. Validity of daily self-pulse palpation for atrial fibrillation screening in patients 65 years and older: a cross-sectional study. *PLoS Med* 2020;**17**:e1003063.
- Halcox JPJ, Wareham K, Cardew A, Gilmore M, Barry JP, Phillips C, Gravenor MB. Assessment of remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study. *Circulation* 2017;**136**: 1784–1794.
- Svennberg E, Engdahl J, Al-Khalili F, Friberg L, Frykman V, Rosenqvist M. Mass screening for untreated atrial fibrillation: the STROKESTOP study. *Circulation* 2015;**131**: 2176–2184.
- Poulsen PB, Hemmingsen U, Melgaard TA, Elleby HB, Wedell-Wedellsborg D, Dybro L, Lund IM, Dixen U, Frost L. Feasibility of screening for atrial fibrillation in a domiciliary setting: opportunistic one-time screening at preventive home visits in municipalities. *Scand Cardiovasc J* 2022;**56**:243–246.
- Senoo K, Yukawa A, Ohkura T, Shoji K, Takigami M, Iwakoshi H, Nishimura T, Nakata M, Teramukai S, Matoba S. Screening for untreated atrial fibrillation in the elderly population: a community-based study. *PLoS ONE* 2022;**17**:e0269506.

- 41. Chen Y, Huang QF, Sheng CS, Zhang W, Shao S, Wang D, Cheng YB, Wang Y, Guo QH, Zhang DY, Li Y, Lowres N, Freedman B, Wang JG. Detection rate and treatment gap for atrial fibrillation identified through screening in community health centers in China (AF-CATCH): a prospective multicenter study. *PLoS Med* 2020;**17**: e1003146.
- Zaprutko T, Zaprutko J, Baszko A, Sawicka D, Szalek A, Dymecka M, Telec W, Kopciuch D, Ratajczak P, Michalak M, Rafal D, Szyszka A, Nowakowska E. Feasibility of atrial fibrillation screening with Mobile health technologies at pharmacies. J Cardiovasc Pharmacol Ther 2020;25:142–151.
- 43. Orchard J, Li J, Freedman B, Webster R, Salkeld G, Hespe C, Gallagher R, Patel A, Kamel B, Neubeck L, Lowres N. Atrial fibrillation screen, management, and guideline-recommended therapy in the rural primary care setting: a cross-sectional study and cost-effectiveness analysis of eHealth tools to support all stages of screening. J Am Heart Assoc 2020;9:e017080.
- 44. Gwynn J, Gwynne K, Rodrigues R, Thompson S, Bolton G, Dimitropoulos Y, Dulvari N, Finlayson H, Hamilton S, Lawrence M, MacNiven R, Neubeck L, Rambaldini B, Taylor K, Wright D, Freedman B. Atrial fibrillation in indigenous Australians: a multi-site screening study using a single-lead ECG device in aboriginal primary health settings. *Heart Lung Circ* 2021;**30**:267–274.
- Sun W, Freedman B, Martinez C, Wallenhorst C, Yan BP. Atrial fibrillation detected by single time-point handheld electrocardiogram screening and the risk of ischemic stroke. Thromb Haemost 2022;**122**:286–294.
- 46. Nicole Verbiest-van Gurp, Uittenbogaart SB, Lucassen WAM, Erkens PMG, Knottnerus JA, Winkens B, Stoffers H, van Weert H. Detection of atrial fibrillation in primary care with radial pulse palpation, electronic blood pressure measurement and handheld single-lead electrocardiography: a diagnostic accuracy study. *BMJ Open* 2022;**12**:e059172.
- Jatau AI, Bereznicki LR, Wimmer BC, Bezabhe WM, Peterson GM. Improving knowledge and early detection of atrial fibrillation through a community-based opportunistic screening program: what's your beat? *Int J Environ Res Public Health* 2022;**19**: 6860.
- Denas G, Battaggia A, Fusello M, Franco-Novelletto B, Cancian M, Scalisi A, Pengo V. General population screening for atrial fibrillation with an automated rhythmdetection blood pressure device. *Int J Cardiol* 2021;**322**:265–270.

- 49. Zhang W, Chen Y, Miao CY, Huang QF, Sheng CS, Shao S, Wang D, Xu SK, Lei L, Zhang D, Chen YL, Hu LX, Xia JH, Ye XF, Cheng YB, Wang Y, Guo QH, Li Y, Lowres N, Freedman B, Wang JG, Coordinators A-Cl. Quarterly versus annual ECG screening for atrial fibrillation in older Chinese individuals (AF-CATCH): a prospective, randomised controlled trial. *Lancet Healthy Longevity* 2021;**2**:E470–E478.
- Lubitz SA, Atlas SJ, Ashburner JM, Lipsanopoulos ATT, Borowsky LH, Guan W, Khurshid S, Ellinor PT, Chang Y, McManus DD, Singer DE. Screening for atrial fibrillation in older adults at primary care visits: VITAL-AF randomized controlled trial. *Circulation* 2022;**145**:946–954.
- Watanabe E, Takahashi N, Aronson R, Ohsawa A, Ishibashi Y, Murakawa Y, SCAN-AF Investigators. Systematic screening for atrial fibrillation in patients at moderate-to-high risk of stroke- potential to increase the atrial fibrillation detection rate (SCAN-AF). *Circ J* 2022;86:1245–1251.
- Philippsen TJ, Christensen LS, Hansen MG, Dahl JS, Brandes A. Detection of subclinical atrial fibrillation in high-risk patients using an insertable cardiac monitor. *JACC Clin Electrophysiol* 2017;**3**:1557–1564.
- 53. Deguchi Y, Amino M, Adachi K, Matsuzaki A, Iwata O, Yoshioka K, Watanabe E, Tanabe T. Circadian distribution of paroxysmal atrial fibrillation in patients with and without structural heart disease in untreated state. *Ann Noninvasive Electrocardiol* 2009;**14**:280–289.
- 54. Rizas KD, Freyer L, Sappler N, von Stulpnagel L, Spielbichler P, Krasniqi A, Schreinlechner M, Wenner FN, Theurl F, Behroz A, Eiffener E, Klemm MP, Schneidewind A, Zens M, Dolejsi T, Mansmann U, Massberg S, Bauer A. Smartphone-based screening for atrial fibrillation: a pragmatic randomized clinical trial. Nat Med 2022**28**:1823–1830.
- 55. Wahler S, Birkemeyer R, Alexopoulos D, Siudak Z, Muller A, von der Schulenburg JM. Cost-effectiveness of a photopethysmographic procedure for screening for atrial fibrillation in 6 European countries. *Health Econ Rev* 2022;**12**:17.
- 56. Birkemeyer R, Muller A, Wahler S, von der Schulenburg JM. A cost-effectiveness analysis model of preventicus atrial fibrillation screening from the point of view of statutory health insurance in Germany. *Health Econ Rev* 2020;**10**:16.